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Preface 
This dissertation contains five chapters comprising the majority of my investigations into natural 
products produced by both cultured and uncultured bacteria.  Chapter 1 begins with an introduction 
to natural products and the need for new antibiotics.    A portion of this chapter was published in a 
review article during my graduate studies. (Schofield MM and Sherman DH. 2013. “Meta-omic 
characterization of bacterial gene clusters for natural product biosynthesis.” Curr. Opin. 
Biotechnol. 2013, 24(6):1151-8).   
 
Chapter 2 describes my efforts to identify a novel natural product from a cultured bacterium through 
the targeted screen of an extensive extract library.  The work described in this chapter was previously 
published in a co-first author paper in the Journal of the American Chemical Society. (Tripathi 
A, Schofield MM, Chlipala GE, Schultz PJ, Yim I, Newmister SA, Nusca TD, Scaglione JB, 
Hanna PC, Tamayo-Castillo G, Sherman DH. “Baulamycins A and B, Broad-Spectrum 
Antibiotics Identified as Inhibitors of Siderophore Biosynthesis in Staphylococcus 
aureus and Bacillus anthracis.”  J. Am. Chem. Soc. 2014, 136(4):1579-86). 
 
Chapter 3 delves into my metagenomic studies on the uncultured bacterium that makes the anti-
cancer natural product ET-743.  A manuscript encompassing portions of this chapter was 
prepared for submission to the Proceedings of the National Academy of Sciences of the USA for 
peer review during the completion of my thesis work.  
 
Chapter 4 continues my ongoing investigation into ET-743.  In this chapter, I describe our 
biochemical breakthroughs to characterize the enzymes involved in the biosynthesis of the ET-
743 tetrahydroisoquinoline core.   
 
Finally, I discuss ongoing and potential future directions for these research projects in Chapter 5.   
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Chapter 1 
Background and Introduction 
 
1.1 A Need for New Medicines  
Every year, at least two million people in the U.S. acquire infections that cannot be effectively 
treated with available antibiotics. These antibiotic-resistant illnesses directly kill 23,000 people 
annually, and even more die of associated medical complications (1).     
 
Despite these frightening statistics, researchers have identified few new drugs to treat resistant 
infections.  In fact, the vast majority of today’s antibiotics belong to classes that were discovered 
before 1970 (2). Members from each of these of these drug classes possess a common core 
structure, or scaffold (Figure 1-1).  When bacteria begin to develop resistance to an antibiotic, 
synthetic chemists modify the core scaffold with chemical groups that improve the drug’s 
potency or target specificity.  The end result is multiple generations of each antibiotic class 
(Figure 1-1). 
 
This semi-synthetic method of drug development is an effective short-term strategy for fighting 
antibiotic resistance.  However, it is not enough.  Bacteria are acquiring resistance to new 
generations of antibiotics faster than scientists are able to synthetically tailor drugs and receive 
marketing approval (3).  Many bacteria have even developed mechanisms that now provide 
resistance against an entire antibiotic class (2).  For example, the generations of penicillin 
antibiotics each possess a β-lactam ring that inhibits cell wall biosynthesis (Figure 1-1).  
However, some bacteria possess β-lactamase enzymes that hydrolyze the core scaffold of these 
antibiotics and render them useless.  Since the introduction of new generations of penicillin and 
other β-lactam antibiotic classes (e.g. cephalosporins, monobactams, and carbapenems), the 
number and diversity of β-lactamases has skyrocketed (4).  Today, there are over 1,000 
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recognized β-lactamases found in a wide range of microbial species, severely limiting our ability 
to utilize many β-lactam antibiotics (5).  
 
 
Figure 1-1. Most of today’s antibiotics are created by synthetically tailoring a conserved chemical 
core.      
The preserved scaffolds are depicted in black while added chemical groups are shown in red for the first 
three generations of each antibiotic class. The original year of discovery for each antibiotic class is also 
shown. Modified from Fischbach et. al. 2009 and Walsh et al. 2014 (6, 7). 
 
Antibiotic resistance is a huge public health concern, but bacteria are not the only lifeforms that 
acquire resistance to currently marketed medicines.  Viruses (8, 9), fungi (10), and even cancers 
(11, 12) are continually developing resistance to marketed antivirals, antifungals, and 
chemotherapeutic medicines.  Finding new medicines is critical to ensure that we can continue to 
protect ourselves from drug resistant infections.  New drugs that possess both a novel core 
scaffold and molecular target may help delay the development of resistance mechanisms (3).  
The biggest challenge is finding sources for new medicines.      
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1.2  Natural products provide unique and desperately needed chemical scaffolds.  
Our surrounding environment provides one important source for new medicines.  Mankind has 
relied on nature to treat different ailments for millennia.  Early physicians collected plants, 
animals, and sediments from their environment to create elixirs and salves that were used as 
some of the world’s first pharmaceuticals.  Although not all of these unique concoctions were 
effective, the process of trial and error allowed early physicians to identify effective medicine 
sources (13).  Even today, many cultures throughout the world rely on herbal remedies that have 
been passed down for generations to treat pain and disease (14).   
 
Figure 1-2. Natural products are an old but effective source of medicine. 
A.) The natural product aspirin derived from willow bark.  B.) The antimalarial artemsinin from the 
Chinese herb Artemisia. C.) The natural product morphine derived from opium poppies. D.) Penicillins 
are a class of antibiotics originally isolated from Penicillium fungi.     
 
The most successful of these natural remedies have a strong scientific basis.  Plants, animals, and 
bacteria are all capable of producing complex and bioactive small molecules called natural 
products.  Today, we have the scientific ability to identify the natural product responsible for the 
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therapeutic effect in many of the most potent of these ancient remedies.  For example, the 
compound salicin (aspirin, Figure 1-2A) is the active ingredient in dried willow bark 
concoctions that have been used in pain relief for the last 6,000 years (13).  The antimalarial 
natural product artemsinin (Figure 1-2B) is responsible for the medicinal effects found in the 
Chinese herb Artemisia annua (14). Civilizations throughout Europe and Asia used poppies in 
medical treatments for thousands of years (Figure 1-2C).  Today, the active ingredient morphine 
is common in pain relief and surgeries (15).   
 
The continued prevalence of natural products in modern medicine is largely due to their potency 
and unique chemistry.  Unlike manmade compounds, most natural products have elaborate 
structures with complex three-dimensional shapes (16). Evolution has also already tailored these 
unique compounds to penetrate membranes and interact with biological targets (17).  This gives 
natural products a huge advantage over synthetic compounds, which often have to be tested and 
repeatedly fine-tuned before achieving any kind of biological relevance (17, 18).   
 
With so many advantages, it is unsurprising that the majority of drugs currently marketed in the 
U.S. are natural products or natural product-inspired derivatives (19, 20).  However, natural 
products do have some disadvantages.  It is not always environmentally sustainable to harvest 
animals, plants, or other macroorganisms to acquire marketable amounts of the potent 
compounds.  Bark from the evergreen tree Taxus brevifolia, for example, possess the powerful 
chemotherapeutic natural product taxol (21).  But the evergreen tree is an endangered species, 
and large-scale harvest of the compound from the native source has never been an option.  
Fortunately, scientists are sometimes able to develop synthetic methods to produce these 
compounds in the laboratory.  Although synthetic routes to natural products can be effective, 
they are also frequently time-consuming and costly.  For environmental reasons, taxol is 
currently produced by a synthetic method, but its native evergreen producer remains the most 
reliable source for the powerful drug (22).  
1.3 Microorganisms are an important source for natural products     
Fortunately, there are alternative sources of natural products that are economically and 
environmentally sustainable to harvest on a large scale. Alexander Fleming’s discovery of 
penicillin in the 1920s from a Penicillium fungus (Figure 1-2D) gave way to the beginning of 
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the antibiotic age and the widespread use of microbial natural products. Today, microbial natural 
products and their derivatives continue to constitute many currently marketed medicines (Figure 
1-3). 
 
Figure 1-3. Examples of marketed natural products isolated from cultured microorganisms.       
Antibiotic classes are shown in bold.  The depicted compound and the cultured organism that produces it 
are in parentheses.   
 
Microorganisms are ideal sources for unique medicines (23, 24).  They produce a wide variety of 
biologically intriguing compounds that play an important role in an ongoing war against their 
neighbors for environmental resources.  Many microorganisms can also be grown in the 
laboratory using standard techniques.  Since most species reproduce quickly, laboratory 
cultivation can lead to the rapid large-scale production of potent medicines without having a 
negative ecological impact.  Furthermore, microorganisms have simple genomes in comparison 
to plants, animals, or insects.  This permits quick and easy manipulation of the genes responsible 
for production of natural products, potentially helping researchers make more potent or selective 
medicines.      
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Given all of these benefits, it is unsurprising that researchers have identified more than 20,000 
microbial natural products to date (25).  But the sheer abundance of microbes on the planet 
suggests we have not even begun to exploit their true pharmaceutical potential.   
1.4. Uncultivated microorganisms are an unexploited source of novel medicines   
Cultured microorganisms have led to the discovery of many potent natural products used to treat 
a wide range of infections and diseases (Figure 1-3).  However, less than 1% of the world’s 
microorganisms can currently be cultivated in the laboratory using standard techniques (26-28).  
 
Given the pharmaceutical success of natural products from cultured bacteria, it is very likely that 
the world’s uncultured majority could also be hiding a wealth of bioactive compounds.  In fact, 
many natural products—including some currently in clinical trials—are predicted to originate 
from uncultured bacteria (Table 1-1).  These microorganisms may have complex metabolisms 
and require access to specific nutrients or precise environmental conditions to grow outside of 
their native environment.  They are therefore currently considered uncultured.   
Table 1-1. Examples of natural products suspected to originate from uncultured microorganisms.  
Natural products that are currently approved or undergoing clinical trials are indicated with an asterisk.  
 
 
Compound Name Isolated 
Source 
Therapeutic Use Evidence for Microbial Origin 
*Yondelis, ET-743 Tunicate Cancer NRPS origin, FISH studies, meta-
omics (see Chapter 3) 
*Bryostatin 1 Bryozoa Cancer and 
Alzheimer’s 
PKS origin, FISH, PCR studies 
*Hemiasterlin Sponge Cancer Found in diverse sponge species 
Pederin Beetles Cancer PKS origin, similar structure to 
onnamide, meta-omics 
Onnamide Sponge Cancer PKS origin, similar structure to 
pederin, meta-omics 
Patellamides Cyanobacteria, 
Tunicate  
Cancer Meta-omic studies 
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Since researchers have failed to grow these microbes using standard techniques, synthetic 
methods are typically used to access their potent natural products.  However, understanding more 
about their unique biology could one day pave the way for methodologies that permit the growth 
of these microbes in the laboratory (29, 30).  Growth of these elusive microbes could facilitate 
large-scale production of medicines and access to more potent or selective analogues. Even if 
cultivation continues to prove impossible, a better understanding of the microorganism’s biology 
could facilitate access to these medicines.  Understanding their biosynthetic gene clusters could 
permit new routes to harness their natural products, either through heterologous expression of 
their complete gene clusters in cultured bacteria or through manipulation of key enzymes (31).    
1.5. Summary and Chapter Outline  
Natural products represent a very old but important and successful source of novel medicines for 
different diseases and ailments.  Their ability to provide novel chemical scaffolds with unique 
molecular targets is increasingly important as bacteria, viruses, fungi, and cancers develop 
resistance to marketed medicines.  Microorganisms in particular provide a critical source of 
natural products that can be both economically and environmentally sustainable to produce on a 
larger scale.  To maximize the discovery of new medicines, researchers need to simultaneously 
explore the natural products of both cultured and currently uncultured microorganisms.     
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Figure 1-4. An outline of my dissertation     
Chapter 2 describes a targeted high throughput screen from an extract library to identify novel natural 
products.  Chapters 3 and 4 outline techniques to access the products of uncultured microorganisms.  In 
chapter 3, we utilize metagenomic methods to understand an uncultured microorganism.  In chapter 4, we 
use this new information to begin work that could one day enable us to access its natural product.  
Chapter 5 describes future directions and ongoing work for both of these projects.   
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My dissertation is equally split between two distinct thesis projects exploring new ways to access 
microbial natural products (Figure 1-4).  The first project (chapter 2) utilizes a natural product 
extract library derived from cultured bacteria to identify medicines with both a novel chemical 
scaffold and a unique molecular target.  Screening the expansive library for inhibitors of an 
enzyme that facilitates iron acquisition in pathogenic bacteria led to the discovery of a new class 
of antibiotics.   
 
My second project (chapters 3 and 4) explores routes to understand and harness the natural 
products of bacteria that cannot currently be grown in the laboratory.  In chapter 3, we used 
metagenomic methods to uncover the long elusive genome of an endosymbiotic bacterium 
capable of making a powerful and clinically approved chemotherapeutic drug called ET-743.  
We then analyzed the genome’s primary and secondary metabolism, gaining significant insight 
into the microorganism’s biology, the production of its bioactive natural product, and its long-
term evolution with its animal host.   
 
In chapter 4, we utilized the newfound knowledge from this uncultured genome to take the first 
steps toward more efficient access of its chemotherapeutic natural product and new analogues.  
We cloned the genes responsible for production of the unique core of the natural product and 
successfully expressed them in a cultured, heterologous host.  We then provided biochemical 
evidence for one enzyme in the biosynthesis of the natural product and demonstrated that it can 
be manipulated to potentially allow for the creation of new analogues.  
 
Chapter 5 includes a summary of results along with future and ongoing areas of study for each 
project.  
 
1.6 Notes 
All photographs in Figure 1.1 are licensed under creative commons 2.0 or 3.0 licenses.  The 
original photographs were altered to include an overlay of the chemical structures of the 
corresponding natural products.  Credits are as follows: A) Photograph by Ronald Saunders. B) 
Photograph by Kristin Peters. C) Photograph by Wolfgang Horlacher. D) Photograph by Steve 
Jurvetson. 
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Chapter 2 
Accessing natural products from cultured bacteria:  
Discovery of the broad-spectrum baulamycin antibiotics  
 
2.1 Introduction 
The rapid ability of pathogens to develop resistance to antibiotics is endangering the 
management of a multitude of serious infections (6, 32, 33). In alarming contrast to the increase 
of bacterial adaptation to currently marketed drugs, the discovery of novel classes of 
antimicrobials is on the decline (2). Although the majority of pharmaceutical efforts during the 
past six decades have focused on the synthetic enhancement of a limited set of unique core 
scaffolds, a more sustainable route to combat antibiotic resistance is the discovery of novel 
chemical structures possessing unique microbial targets (6, 34). Iron acquisition mechanisms in 
particular may represent effective antimicrobial targets that present substantial hurdles to 
bacterial antibiotic resistance (35). Iron is required for growth and survival of bacteria but 
remains tightly regulated in the mammalian host. Many pathogenic Gram-positive and Gram-
negative bacteria utilize virulence-associated siderophores to scavenge iron from this restricted 
environment and return it to the microbial cell (36). Although previous studies have corroborated 
siderophore biosynthetic enzymes as effective drug targets through the tailoring of established 
chemical scaffolds (37-41), no novel chemical structures have been identified. 
 
In our efforts to identify new structural antibiotic classes with inhibitory activity against 
siderophore biosynthetic enzymes, we selected the Gram-positive bacteria, methicillin-resistant 
Staphylococcus aureus (MRSA) and Bacillus anthracis, as model systems. The “superbug” 
MRSA is a major public health concern, attributed to more than 18,000 deaths a year in the 
United States (6, 41). In contrast, the spore-forming microorganism B. anthracis is the causative 
agent of anthrax. The ability of the bacterium to quickly achieve high concentrations within 
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infected hosts makes it a serious bioterrorism threat, with mortality rates for inhalational 
infection historically reaching as high as 94% (42).  
 
Both pathogens are strongly associated with antimicrobial resistance, and their siderophore 
biosynthetic pathways have been extensively characterized (43, 44). The siderophores 
staphyloferrin B (2) of S. aureus (45-50) and petrobactin (5) of B. anthracis (51-58) in particular 
have been shown to be critical for survival in iron-limited environments. 
 
Figure 2-1. Biosynthesis of virulence-associated siderophores  
(A) staphyloferrin B in S. aureus (B) petrobactin in B. anthracis. The target biosynthetic enzymes, SbnE 
and AsbA, are highlighted by the yellow circles 
 
The biosynthetic pathways for both siderophores involve a type A nonribosomal peptide 
synthetase independent siderophore (NIS) synthetase, SbnE (Figure 2-1A) in staphyloferrin B, 
and AsbA (Figure 2-1B) in petrobactin. Type A NIS synthetases are a unique class of enzymes 
found within siderophore biosynthetic pathways of a number of pathogenic bacteria, including 
Shigella flexneri, Escherichia coli, and Salmonella typhimurium (59, 60). These enzymes 
catalyze the condensation of citric acid with either a polyamine or amino alcohol substrate in an 
ATP-dependent reaction (59, 60). Since type A NIS synthetases share similar catalytic 
mechanisms and substrate preferences, we sought to identify novel antibiotics against S. aureus 
or B. anthracis that could also serve as broad- spectrum antibiotics against other NIS synthetase-
containing pathogens. 
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2.2 Results  
2.2.1 High-Throughput Screening for Inhibitors of Siderophore Biosynthesis Derived from 
Natural Product Extracts 
Fueled by the need to identify a new structural class of antibiotics, we selected a marine 
microbial-derived natural product extract (NPE) library to identify inhibitors of NIS synthetases 
in S. aureus and B. anthracis. The majority of currently marketed drugs are derived from natural 
products (19, 20), and the marine environment in particular is thought to be an underexplored 
source of novel chemical structures (23). We developed an enzymatic high-throughput assay 
specific to SbnE and AsbA and adapted it to a malachite green reporter system (61-63).  The 
assay was then queried against a library of 19,855 marine microbial-derived NPEs to identify 
inhibitors of enzyme activity (Figure 2-2). The NPEs in this library are primarily from marine-
derived microorganisms collected in Costa Rica, Panama, and Papua New Guinea. Screening 
SbnE and AsbA in parallel limited the number of false positives and provided a convenient 
method for prioritization of active extracts. Two rounds of screening yielded 33 strains with 
reater than 70% inhibition against SbnE at 7.5 µg/mL and 22 strains with extracts showing 
greater than 50% inhibition against AsbA at 75 µg/mL (Figure 2-2). The higher frequency and 
activity of extracts against SbnE is likely due to the lower enzyme concentration (25 nM) 
compared to the AsbA (100 nM) utilized in screening. These were the lowest enzyme 
concentrations for each respective assay that produced a response fit for screening (Figure 2-8 in 
Supporting Information [SI]). Low enzyme concentrations were desired to maximize the 
likelihood of detecting extracts possessing low-abundance bioactive components. 
 
Among active extracts, Streptomyces tempisquensis (Figure 2-10 in SI) was of particular interest 
due to its high activity against both SbnE (95.9%) and AsbA (90.2%) (Figure 2-9 in SI). The 
strain was originally isolated from sediments collected in Playa Grande, Costa Rica (−85° 49’ 
39.8’’, 10° 18’ 39.8’’) near Las Baulas National Marine Park. 
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Figure 2-2. Triage of hits derived during high throughput screening of SbnE and AsbA against the 
full microbial NPE library. 
 
2.2.2. Isolation and Structural Elucidation of the Baulamycins (6−7) 
An iterative bioassay guided C18 fractionation (Figure 2-11 in SI), and subsequent RP-18 
HPLC purification (Figure 2-12 in SI) yielded two novel bioactive molecules (Figure 2-3), 
baulamycins A (BmcA, compound 6) and B (BmcB, compound 7), whose structures are 
consistent with biogenesis from a type I polyketide synthase pathway. BmcA (compound 6) was 
purified as a light-yellow amorphous solid and possesses a molecular formula of C H O as 
suggested by HRAPCIMS based on [M + H]+ 28 48 6 ion peak at m/z 481.3530 (Figure 2-13 in 
SI). The 1H (Figure 2-14 in SI) and 13C NMR (Figure 2-15 in SI) data, recorded in CD3OD 
indicated the polyketide nature of 6 and indicated the presence of at least three hydroxyl group 
bearing methines with chemical shifts at δ 4.47 (76.5), 4.01 (73.3), and 3.69 (72.5). Further 
analysis of the 1H NMR spectrum of 6 identified 12 aliphatic protons in the region of δH 
0.95−2.77 and six methyl groups at δH 0.77 (d), 0.83 (d), 0.86 (d), 0.88 (d), 1.02 (t), and 1.06 
(d). The 13C NMR and HSQCAD spectra (Figure 2-16 in SI) revealed the presence of four 
quaternary carbons at δC 148.6 (an aromatic carbon), 159.1 (two chemically equivalent aromatic 
carbons), and at δ 218.7 (a carbonyl carbon). The C gCOSY (Figure 2-17 in SI) correlations 
between two equivalent aromatic protons with a signal at δH 6.33, 6.15 and HMBCAD (Figure 
2-18 in SI) correlation between δH 6.33, 6.15 to the equivalent carbons at δC 159.1, 105.9 and 
carbon at δC 148.6 clearly suggested the presence of resorcinol moiety (Table 2-1). Similarly, 
the connectivity from C-1 to C-17 was confirmed by an array of COSY and HMBC couplings in 
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both CD3OD and DMSO-d6 to construct a 17-carbon linear aliphatic chain with a characteristic 
carbonyl carbon at δC 218.7. In addition, COSY correlation was observed between H-1 and 
protons at C-2 along with their HMBC connection to C-3 suggesting an ethyl- ketone terminus 
for molecule 6. Moreover, the COSY and HMBC correlations indicated the branching of an 
aliphatic chain through a methyl group at C-4 (δH 2.77, δC 44.6), C-6 (δH 1.42, δC 29.1), C-8 
(δH 1.53, δC 30.9), and C-16 (δH 1.38, δC 26.6) positions. The position of the hydroxyl group at 
C-11 and C-13 were consistent with the distinctive 1H and 13C chemical shifts at δH 3.69, δC 
72.5 and δH 4.01, δC 73.3, respectively. Furthermore, HMBC showed a correlation from H-1
′ (δH 4.47) to C-2′ (δC 148.6) along with its contiguous COSY correlation to H-14 (δH 
1.88) indicating a branch-point for the aliphatic chain at C-14 through a pendant attachment of 1
′ (hydroxymethyl) resorcinol moiety to complete the structure of BmcA (6) (Table 2-1). 
 
Figure 2-3. Planar structure of baulamycins A (6) and B (7) showing COSY correlation with bold 
bonds and HMBC correlations with arrow. 
 
BmcA (6) consists of seven stereocenters with three hydroxyl-bearing carbons, three methyl-
bearing carbons, and a 2-methylpropane-containing stereocenter. Initial attempts were made to 
obtain absolute stereochemical information through chemical manipulations for at least the 
hydroxyl-bearing chiral centers. However, the relatively low yield of baulamycins rendered this 
approach impractical. Therefore, a nondestructive J-based configuration analysis (JBCA)39 was 
employed to propose the relative configuration of BmcA (6).40−42 We calculated 3JH−H, 
2JC−H, and 3JC−H values using a combination of phase-sensitive double quantum filtered (PS-
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DQF)-COSY, homonuclear 2DJ spectroscopy (HOMO2DJ), gradient- and sensitivity-enhanced 
hetero (ω1) half-filtered TOCSY (HET- LOC-gse) and heteronuclear 2DJ (HET2DJ) spectral 
analyses (Figures 2-19 to 2-21 in SI). 
 
Table 2-1. NMR spectroscopic data for baulamycins A (6) and B (7) in CD3OD at 700 MHz. 
 
 
 
 
 
 
 
 
Baulamycin A (6) Baulamycin B (7) 
 
δC δH, multi (J in Hz) COSY HMBC δC δH 
1 35.1 2.57, dp 2" 1, 2", 2 27.4 2.15 
  
2.49, dp 2" 1, 2", 2 
  2 7.8 1.02, t  (6.9, 7.3) 1" 1, 1", 2 
  3 218.7 
   
214.6 
 4 44.6 2.77, ddq (3.2, 6.7, 8.0) 3 1, 3, 19 43.9 2.70 
5 41.7 1.73, ddd (3.2, 5.0, 11.0) 2 1, 2, 4 41.8 1.72,  
  
0.98, ddd (6.7, 8.0, 11.0) 4 
  
0.97 
6 29.1 1.42, ddddq (3.0, 3.2, 5.0, 13.0) 3, 5 6, 18 29.2 1.44 
7 46.3 1.22, ddd (3.0, 11.0, 13.0) 6 17, 18 46.0 1.22  
  
0.95, ddd (3.2, 5.0, 11.0) 3 17, 18 
 
0.95 
8 30.9 1.53, ddddq (3.0, 5.0, 8.5, 13.0) 5, 7 5, 7, 17 31.0 1.55 
9 33.0 1.33, dddd (3.0, 3.0, 10.6) 6, 8 9, 17 33.4 1.34  
  
1.19, dddd (8.5, 9.0, 10.6) 6, 8 7, 5 
 
1.21 
10 35.4 1.41, dddd (9.0, 11.0, 11.6) 7, 9 11, 17 35.1 1.40  
  
1.39, dddd (3.0, 4.0, 11.6) 7, 9 
  
1.38 
11 72.5 3.69, dddd (8.0, 11.0, 12.0) 8, 10 7, 8. 11 72.2 3.72 
12 40.6 1.79, ddd (8.0, 7.2, 11.0) 9, 11 
 
40.2 1.80,  
  
1.55, ddd (3.1, 3.2, 11.0) 
   
1.50 
13 73.3 4.01, dt (9.9, 3.4) 10, 12 1', 9, 13 73.0 3.99 
14 48.5 1.88, ddq (7.7, 7.0) 11, 13 1', 11, 14 48.7 1.80 
15 37.3 1.21, m 12, 14 
 
37.0 1.20 
16 26.6 1.38, m 13, 15 
 
26.6 1.38 
17 22.5 0.83, d (6.5) 14 13, 14 22.4 0.82 
18 23.3 0.77, d (6.5) 14 13, 14 23.3 0.77 
19 20.3 0.86, d (6.6) 6 5, 6, 7 20.1 0.85 
20 20.5 0.88, d (6.5) 4 3, 4, 5 20.2 0.88 
21 17.9 1.06, d (6.9) 2 1, 2, 3 18.0 1.01 
1' 76.5 4.47, d (7.0) 12 2', 3', 8, 13, 11 76.4 4.50 
2' 148.6 
   
148.2 
 3' 105.9 6.33, d (2.2) 5' 1', 2', 3', 4', 106.1 6.35 
4' 159.1 
   
158.5 
 5' 101.9 6.15, t (2.2) 3' 3', 4' 101.8 6.16 
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The relative configurations of stereocenters (C11−C13− C14−C1′) in compound 6 established 
by JBCA are as follows. At the C1′−C14 axis, large coupling constants 3JH1′−H14 ≈ 7.2 Hz 
and 2JC′−H14 ≈ 5.2 Hz inferred their anti and gauche orientations, respectively (64) (Figure 2-
4). For the C14−C13 bond, the large 3JH14−H13 ≈ 7.7 Hz suggested anti orientation, which was 
also supported by the observed ROESY correlations (Figure 2-21 in SI). An additional large 
2JC13−H14 ≈ 7.0 Hz was indicative of the gauche orientation between O-13 and H-1439 
(Figure 2-4). Further, we sliced the HOMO2DJ spectrum at δH 4.01 (H-13), suggesting a large 
coupling constant between H13−H12a and a small value between H13−H12b, indicative of anti 
and gauche orientations, respectively (Figure 2-4). For the C12−C11 moiety, we sliced the 
HOMO2DJ spectrum at δH 3.69 (H-11) to yield 3JH12a−H11 ≈ 8.0 Hz and 3JH12a−H11 ≈ 3.2 
Hz, suggesting anti and gauche orientation, respectively (Figure 2-4). Furthermore, large 
coupling constants were recorded for 2JC11−H12a ≈ 6.8 Hz and 2JC11−H12b ≈ 7.2 Hz, clearly 
indicating gauche orientations between O-11 and H-12a/H-12b39 (Figure 2-4). Moving down 
the axis over the C11−C10 moiety, large coupling constants between H-11/H-10a, H-11/H10b, 
and C11/H10a suggested gauche orientation between O-11 and H-10a. Hence, the relative 
configurations at C1′, C14, C13, and C11 were proposed as 1′R*, 14S*, 13R*, and 11R*, 
respectively (Figure 2-3). 
 
Establishment of the relative orientation of protons associated with nonchiral C-10 and C-9 was 
necessary to measure the stereochemistry of subsequent chiral carbons (C8−C4). We sliced both 
HOMO2DJ and PS-DQF-COSY spectra at δH 1.41, 1.39 (H-10a, H-10b) and δH 1.19, 1.33 (H- 
10a, H-10b), respectively. The slicing provided large coupling constants between H-10a/H-9b 
and small between H-10a/H- 9a suggesting anti and gauche orientations, respectively (Figure2-
5). Correspondingly, for the C9−C8 axis, calculations yielded 3JH9b−H8 ≈ 8.5 Hz (large) and 
3JH9a−H8 ≈ 3.0 Hz (small) indicating anti and gauche conformations, respectively (Figure 2-5). 
Furthermore, the ROESY correlations and small coupling values obtained from 3JC7−H9a ≈ 2.0 
Hz and 3JC7−H9b ≈ 2.1 Hz confirmed the gauche orientations between C7 and H-9a/H-9b 
facilitating assignment of the relative conformation of H-9a and H-9b at C9 (Figure 2-5). 
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Figure 2-4: H-H, C-H coupling values and relative configuration determined for C1’-C11. Arrows 
showing ROESY correlations. 
 
For the C9−C8 axis, the observation of large 3JH8−H9b (8.5 Hz) and 3JC19−H9a (8.0 Hz) 
values indicated that H-8 and H9b as well as C-19 and H-9a are in the anti orientation. The 
relative configuration at C8 was established to be R* according to the ROE between H-8 and H-
9a (Figure 2-5). For the C8/C7 bond, the relationship of C19/H-7b was revealed as anti on the 
basis of a large 3JC19−H7b ≈ 9.0 Hz value. Another large coupling value (3JH7a‐H8 ≈ 13.0 
Hz) and corresponding small coupling value between C6 and H-8 (3JC6−H8 ≈ −2.4 Hz) led us to 
assign the relative conformation of H-7a and H-7b at C7 (Figure 2-5). For the C7/C6 bond, the 
observation of small coupling values (3JH7a‐H6 ≈ 3.0 Hz and 3J7b‐H6 ≈ 3.2 Hz) along with 
apparent ROE between H-6 and H-7a/H-7b suggested gauche orientation between H-6 and H-
7a/H7b, establishing relative configuration at C6 as S* (Figure 2-5). 
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For C6 and C5, a large 3JH6−H5b value (∼13.0 Hz) and small 3JH6−H5a value (∼5.0 Hz) 
revealed that H-6/H-5b and H-6/H- 5a possess anti and gauche relationships, respectively. Addi- 
tionally, small 3JC4−H6 ≈ 2.0 Hz and 3JC7−H5a ≈ −1.8 Hz values as well as observed ROE 
between H-5a and H-6 revealed the relative conformation of H-5a and H-5b at C5 (Figure 2-5). 
For the C5/C4 axis, large 3JH5b−H4 ≈ 8.0 Hz and small 3JH5a−H4 ≈ 3.2 Hz coupling values 
were obtained from HOMO2DJ and PS-DQF-COSY indicating anti and gauche conformations, 
respectively. In addition, an anti orientation of the C21 and H- 5a atoms was deduced from the 
large 3JC21−H15a ≈ 11.0 Hz value obtained from HETLOC-gse spectrum. Further, in the 
ROESY spectrum, ROEs between H-5a/H-4, H-4/H-6, and H-6/H-21 were observed. Taking 
these data into consideration, the relative configuration at C4 was proved to be R*. Therefore, 
the relative configuration for C10−C4 moiety was anticipated as 8R*, 6S* and 4R*, respectively, 
in BmcA (6). 
 
Figure 2-5: H-H, C-H coupling values and relative configuration determined for C10-C4. Arrows 
showing ROESY correlations. 
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BmcB (7) was isolated by RP-18-HPLC from the same C18 fraction containing compound 6. 
The HRESIMS of the molecule provided a molecular formula of C27H46O6 showing a [M + H]+ 
ion peak at 467.3171 (Figure 2-26 in SI). Moreover, baulamycin B (7) had high structural 
similarity to 6, as evidenced by nearly identical 1H and 13C NMR chemical shifts when 
measured in CD3OD (Table 2-1). However, it displayed a subtle difference toward the carbonyl 
terminus, revealing the absence of terminal ethyl protons and substituting with a terminal methyl 
singlet at δH 2.18 in the 1H NMR spectrum of compound 7 (Figure 2-27 in SI). The relative 
stereochemistry from C1′−C10 and C5−C3 were proposed to be identical to those of 6 on the 
basis of highly comparable NMR spectroscopy data (Figures 2-27 to 2-31 in SI). 
2.2.3. Assessment of the in vitro Biological Activity of Compounds against Purified NIS 
Enzymes 
The malachite green-based bioassay was next employed to assess the dose response of novel 
compounds BmcA (6) and BmcB (7) against purified SbnE and AsbA (Table 2-2). Both 
compounds exhibited in vitro bioactivity against SbnE, with IC50 values of 4.8 µM and 19 µM 
for BmcA and BmcB, respectively (Figure 2-6A). Inhibition was also observed against AsbA, 
with IC50 values of 180 µM and 200 µM for BmcA and BmcB, respectively (Figure 2-6B). The 
significant difference in apparent inhibition is likely due to the different enzyme concentrations 
used in the dose response assays, 25 nM for SbnE and 100 nM for AsbA (Figure 2-8 in SI). The 
assays were originally optimized at these enzyme concentrations to maximize the detection of 
extracts containing low levels of bioactive components during screening. 
 
 
 
 
 20 
 
Figure 2-6. In vitro and live culture studies of baulamycin bioactivity. 
(A−C) In vitro bioactivities against purified enzyme recorded for BmcA and BmcB against the NIS 
synthetase (A) SbnE, (B) AsbA, or (C) AsbB. (D−H) BmcA inhibition against live cultures of microbial 
strains (D) S. aureus (Newman), (E) B. anthracis (Sterne 34F2), (F) MRSA (USA 300), (G) S. flexneri 
(BS103), or (H) E. coli (MC 1061) in iron-depleted (IDM) or iron-rich (IRM) media. The y- axis 
represents a comparison of the optical densities of inhibitor- treated (ODI) and DMSO control-treated 
(ODC) cultures. Assays were conducted in duplicate due to the current limited availability of the 
baulamycins. 
 
 21 
As a next step to address whether the baulamycins selectively inhibited type A over other NIS 
synthetase subfamilies, we explored the activity of both compounds against the petrobactin 
biosynthetic, type C NIS synthetase, AsbB. While type A NIS synthetases prefer citric acid as a 
substrate, type C enzymes generally utilize citric or succinic acid derivatives often found as 
complex intermediates within their respective siderophore biosynthetic pathways (59). In the 
petrobactin pathway, AsbB catalyzes condensation of a second molecule of spermidine with 
either N8-citryl-spermidine (compound 3) or N1-(3,4- DHB)-N8-citryl spermidine (compound 4) 
(58). Interestingly, recent work in our laboratory also demonstrates AsbB to be more flexible in 
substrate selection and capable of partial compensation for AsbA activity in vitro (58). Despite 
these findings, dose response studies revealed inhibition against AsbB to be negligible for both 
BmcA and BmcB (Figure 2-6C). These data indicate that both natural products are more potent 
in vitro against the type A NIS synthetases SbnE and AsbA than against the type C subfamily 
member AsbB. 
 
Enzymatic 
Target 
NIS Synthetase 
Classification 
Associated 
Microbial Strain 
Associated Siderophore  BmcA IC50 
(µM) 
BmcB IC50 
(µM) 
SbnE Type A S. aureus Staphyloferrin B 4.8 19 
AsbA Type A B. anthracis Petrobactin 180 200 
AsbB Type C B. anthracis Petrobactin > 1000 > 1000 
Table 2-2. In vitro bioactivity analysis of the baulamycins against purified enzymes.   
The IC50 values were determined through the NIS-tailored malachite green assay. 
 
2.2.4. Initial Enzyme Mechanism of Inhibition Studies. 
To investigate how the more potent of the two compounds, BmcA (6), inhibits SbnE and AsbA 
enzymatic activity, we monitored NIS synthetase ATP turnover using a previously described 2-
amino-6-mercapto-7-methylpurine ribonucleoside (MESG) kinetic pyrophosphate detection 
assay (65, 66). These experiments were conducted by varying a single substrate and holding 
remaining reaction components at a constant saturating level in the presence and absence of 
inhibitor. The resulting double reciprocal (Lineweaver−Burk) plots confirmed that kinetic 
parameters closely matched previously reported values for both enzymes against varied citrate 
concentrations (Table 2-4 in SI) (48, 58). The plots suggested that BmcA inhibits both enzymes 
in a reversible, competitive manner with respect to citric acid, the corresponding polyamine, and 
ATP (Figure 2-32, Table 2-4 in SI). Although kinetic assays were only conducted with BmcA 
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due to its higher potency and availability (obtained in substantially higher yield from S. 
tempisquensis), it is reasonable to expect that BmcB also possesses these inhibition patterns. 
 
A replot of slopes derived from the Lineweaver−Burk plot versus inhibitor concentration also 
enabled an initial investigation into the inhibition constants (Ki values) for BmcA against both 
enzymes (Table 2-4 in SI) (67). Interestingly, the inhibitor constants were lowest for citric acid 
(SbnE: 50 µM; AsbA: 110 µM) followed by the polyamine substrate (SbnE: 210 µM; AsbA: 170 
µM) and ATP (SbnE: 680 µM; AsbA: 230 µM). This is surprising, given the polar nature of 
citric acid in comparison to that of the baulamycins. The explanation for this likely depends on 
the structure and substrate binding sites in the proteins. Although no structural studies have yet 
been conducted with SbnE or AsbA, the crystal structures of AsbB and the achromobactin type 
A NIS synthetase in Pectobacterium chrysanthemi have been determined (58, 61). Both reveal a 
single binding pocket that houses substrates and intermediates during catalysis. Elucidation of 
the differences in the structures of SbnE, AsbA, and these other NIS synthetases could shed light 
on the exact mechanism of inhibition exerted by the baulamycins and their complete lack of 
activity against AsbB. Efforts to acquire X-ray crystal structures of both SbnE and AsbA in the 
presence and absence of baulamycin compounds are expected in due course. Additionally, 
mutagenesis and selection of S. tempisquensis should improve the yield of the baulamycins, 
enabling a sufficient amount of these molecules for comprehensive kinetic analysis. 
 
2.2.5 Assessment of Biological Activity against Microbial Cultures. 
Since siderophore biosynthesis is required for bacterial survival in iron-limited environments, a 
selective siderophore synthetase inhibitor would be expected to limit growth only under these 
conditions. Therefore, we monitored bacterial growth in both iron-depleted (IDM) and iron-rich 
(IRM) media conditions in the presence of 6 and 7. We also conducted live culture studies to 
demonstrate the ability of both natural products to penetrate bacteria, an established advantage of 
secondary metabolites over many synthetic chemicals (68). However, due to the extremely low 
yield of the baulamycins from S. tempisquensis, experiments could only be completed in 
duplicate, and the following studies represent an initial assessment of microbial culture 
bioactivity. 
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BmcA was found to inhibit growth of S. aureus (Newman) in both iron-depleted (IC50 = 69 µM) 
and iron-rich (IC50 = 86 µM) conditions (Figure 2-6D, Table 2-3). Similar inhibition was 
observed with B. anthracis (Sterne 34F2) under iron-depleted (IC50 = 110 µM) and iron-rich 
(IC50 = 120 µM) conditions (Figure 2-6E, Table 2-3), suggesting possible secondary targets in 
the cell. In agreement with in vitro findings against purified enzyme, BmcB was significantly 
less potent against S. aureus (Newman) and B. anthracis (Sterne 34F2) (Figure 2-33 in SI). 
 
We next tested the potency of BmcA against a clinically isolated MRSA strain (USA 300). 
Similar to S. aureus (Newman) and B. anthracis (Sterne 34F2), BmcA also inhibited MRSA 
(USA 300) in iron-depleted (IC50 = 130 µM) and iron- rich (IC50 = 130 µM) conditions (Figure 
2-6F, Table 2-3), again suggesting secondary cellular targets. 
 
Microbial Strain Classification Targeted 
Siderophore 
Pathway 
Associated NIS Synthetase  BmcA IRM 
IC50 (µM) 
BmcA IDM 
IC50 (µM) 
S. aureus (Newman) Gram-positive Staphyloferrin B SbnE (A), SbnC (B), SbnF (C) 86 69 
MRSA (USA 300) Gram-positive Staphyloferrin B SbnE (A), SbnC (B), SbnF (C) 130 130 
B. anthracis (Sterne 
34F2) 
Gram-positive Petrobactin AsbA (A), AsbB (C) 120 110 
S. typhimurium Gram-negative Aerobactin IucA (A), IucC (C) > 1000 > 1000 
E. coli (MC 1061) Gram-negative Aerobactin IucA (A), IucC (C) 150 4.2 
S. flexneri (BS103) Gram-negative Aerobactin IucA (A), IucC (C) 46 20 
 
Table 2-3. Bioactivity analysis of the baulamycins against Gram-positive and Gram-negative 
microbial cell cultures.   
Dose response assays were conducted in iron-repleated (IRM) and iron-depleted (IDM) media.   
 
Encouraged by the potency of these compounds on S. aureus and B. anthracis strains, we also 
tested inhibition of the more active BmcA on additional microorganisms possessing NIS 
synthetase siderophore biosynthetic pathways. Aerobactin was the first discovered siderophore to 
be assembled by an NIS synthetase system (59, 69). It contributes to the virulence of a multitude 
of bacteria, including E. coli, and multiple species of Salmonella, Yersinia, and Shigella (56, 70). 
The pathway involves the types A and C NIS synthetases IucA and IucC, respectively (71, 72), 
which share sequence similarity with NIS synthetases found in most other siderophore 
biosynthetic pathways (59, 60). Indeed, SbnE and AsbA appear to be relatives of IucA (59, 60). 
Furthermore, staphyloferrin B biosynthetic enzyme SbnF and petrobactin biosynthetic enzyme 
AsbB share sequence similarity with IucC (59, 60), collectively suggesting that the baulamycins 
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could also inhibit aerobactin-producing bacteria. Thus, we monitored the ability of BmcA to 
inhibit bacterial growth of the aerobactin-producing Gram-negative strains of Shigella flexneri, 
E. coli, and Salmonella typhimurium in iron- depleted and iron-rich conditions (Figure 2-6G,H). 
BmcA inhibited growth of S. flexneri and E. coli cultures in iron- depleted conditions (S. 
flexneri: IC50 = 20 µM; E. coli: IC50 = 4.2 µM) with lower potency in iron-rich conditions (S. 
flexneri: IC50 = 46 µM; E. coli: IC50 = 150 µM). Although increased potency of BmcA against E. 
coli in IDM suggests that this microbe could possess fewer nonspecific cellular drug targets, 
additional studies are required to draw any firm conclusions. While BmcA also appeared to 
inhibit growth of S. typhimurium cultures, the large standard deviations acquired during the assay 
led us to classify the IC50 as above 1 mM in both iron-depleted and -rich conditions (Figure 2-33 
in SI). As improved access to baulamycins becomes possible, follow-up studies will enable more 
extensive analysis of its broad-spectrum antibiotic activity. 
 
The current analysis provides an initial assessment of the ability of BmcA to inhibit growth and 
demonstrates that the molecule is cell permeable. However, inhibition of all target strains under 
both growth conditions suggests that BmcA is acting on some additional cellular targets. Indeed, 
SbnE and AsbA seem to share varying levels of sequence identity with a number of enzymes in 
S. aureus and B. anthracis, including aminoacyl-tRNA synthetases, CoA synthetases, and fatty-
acid CoA ligases in addition to critical enzymes involved in cell envelope biogenesis, inhibition 
of apoptosis, and spore formation (Figure 2-34 in SI) 
 
Finally, the ability of BmcA to inhibit bacterial growth of both Gram-positive and Gram-
negative strains (Table 2-3) classifies it as a broad-spectrum antibiotic. Although BmcB was not 
included in these experiments due to low production by Streptomyces tempisquensis, the 
compound is of a comparable size and possesses similar functional groups, suggesting it also 
could be capable of inhibiting microbial growth and infiltrating the bacteria. On the other hand, 
the decreased chain length and potency of BmcB suggests that longer terminal carbon chains 
may be important in future structure−activity relationship (SAR) studies. 
2.3. Conclusion  
We have identified a new structural class of broad-spectrum antibiotics isolated from a marine 
microbial-derived NPE library. BmcA and BmcB inhibit siderophore biosynthesis, a crucial 
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virulence factor associated with iron sequestration in pathogenic bacteria. Although previous 
studies have validated siderophore biosynthesis as an effective synthetic drug target (37-40), the 
aforementioned study is the first to demonstrate its potential as a target for discovering novel 
chemical scaffolds. Structurally unique drugs like the baulamycins present hurdles for the 
bacterial development of antibiotic resistance. High- throughput screening for natural product 
inhibitors of virulence factors, including those for siderophore biosynthesis, could provide a 
fresh arsenal of chemical scaffolds to combat drug- resistant pathogens. 
 
The baulamycin natural products represent promising lead structures that can be further 
manipulated to improve both potency and target selectivity if required. We have illustrated that 
the compounds are efficacious in vitro and are capable of penetrating bacterial barriers to inhibit 
growth of cultures, including B. anthracis, MRSA, S. flexneri, and E. coli. The ability of the drug 
to inhibit growth of both Gram-positive and Gram- negative bacteria suggests its potential use as 
a broad-spectrum antibiotic. These growth inhibition studies further suggest that the compounds 
possess multiple targets in the microbial cell. Given the simultaneous decline in antibiotic drug 
discovery and increase of multidrug resistant bacteria, the baulamycins may represent an 
auspicious starting-point for expanding discovery efforts against significant human pathogens. 
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2.4. Supplemental Information   
 
 
 
 
 
 
Figure 2-7: Secondary HTS analysis on active NPEs from primary screening. 
(a) SbnE and (b) AsbA.  Green squares represent percent activity in the presence of different 
NPEs, red squares percent activity in the absence of enzyme target, and blue squares percent 
activity with a DMSO vehicle.   
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Figure 2-8. Development of an NIS synthetase assay for screening.  
(a) Testing of the fitness of the NIS hydroxymate-formation assay for HTS. (b) The malachite 
green assay tailored to NIS synthetases SbnE and AsbA.  (c) Optimization of the incubation time 
for SbnE and AsbA reactions.  (d) Optimization of the development time for SbnE and AsbA 
after quenching with the malachite green solution.  (e)Optimization of enzyme concentration for 
the high throughput assays.  
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Figure 2-9. Overview of HTS and Initial Hits.  
(a) Overview of the pilot and full HTS screen against the NPE library. (b) A scatterplot generated with 
MScreen depicting a 384 well plate from the full library screen against SbnE or (c) AsbA. The orange dot 
represents the well containing the active NPE derived from strain Streptomyces tempisquensis, the most 
intriguing hit from the full screen. 
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Figure 2-10: 16S rRNA analysis and alignment.  
The 16S sequence has been given the GenBank accession number KF954543.  
 
 
 
 
 
 
 
 
 
 
 
 
 
(Streptomyces tempisquensis) 
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Figure 2-11: Small and large scale extraction schemes. 
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Figure 2-12. Bioactivity Guided De-replication of NPE. 
Bioactivity Guided De-replication of NPE Streptomyces tempisquensis In vitro activities of C18 flash 
column fractions from and organic extract of XAD-16 bound culture extract from strain Streptomyces 
tempisquensis [Blue: positive control (no enzyme), Red: Streptomyces tempisquensis, Green: negative 
control (no inhibitor)]. A.) In vitro activities of size exclusion fractions originated from active 1W/1A and 
2W/3A C18 fractions. B.) HPLC probe on active size exclusion (SE) fractions for possible bioactive 
molecules (shown under circle). C.) Reverse phase HPLC re-purification of pooled bioactive SE fractions 
(bioactive peaks shown by arrows) 
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Figure 2-13: HRAPCIMS spectrum for baulamycin A (6). 
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Figure 2-14:  1H NMR spectrum of baulamycin A (6) recorded at 700 MHz (in CD3OD). 
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Figure 2-15:  13C NMR spectrum of baulamycin A (6) recorded at 176 MHz. (in CD3OD). 
 
 
Figure 2-16:  HSQCAD NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
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Figure 2-17:  gCOSY NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
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Figure 2-18:  gHMBC NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
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Figure 2-19: HOMO2DJ NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
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Figure 2-20: HETLOC-gse NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
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Figure 2-21: ROESYAD NMR spectrum of baulamycin A (6) recorded at 500 MHz (in CD3OD). 
 40 
 
Figure 2-22: 1H NMR spectrum of baulamycin A (6) recorded at 500 MHz (in DMSO-d6). 
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Figure 2-23: 13C NMR spectrum of baulamycin A (6) recorded at 125 MHz (in DMSO-d6). 
 
 
 
Figure 2-24: HSQCAD NMR spectrum of baulamycin A (6) recorded at 500 MHz (in DMSO-d6). 
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Figure 2-25: PS-DQF-COSY NMR spectrum of baulamycin A (6) recorded at 500 MHz (in DMSO-
d6). 
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Figure 2-26: HRAPCIMS spectra for baulamycin B (7). 
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Figure 2-27: 1H NMR spectrum of baulamycin B (7) recorded at 700 MHz (in CD3OD). 
 
 
 
 
 
Figure 2-28: 13C NMR spectrum of baulamycin B (7) recorded at 700 MHz (in CD3OD). 
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Figure 2-29: gHSQCAD NMR spectrum of baulamycin B (7) recorded at 700 MHz (in CD3OD). 
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Figure 2-30: COSY NMR spectrum of baulamycin B (7) recorded at 700 MHz (in CD3OD). 
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Figure 2-31: HMBCAD NMR spectrum of baulamycin B (7) recorded at 700 MHz (in CD3OD).
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Figure 2-32. Kinetic analysis of the inhibition mechanism of BmcA.  
Double reciprocal plots depicting BmcA inhibition of (a) SbnE as a function of L-DAP, (b) SbnE 
as a function of citrate, (c) SbnE as a function of ATP, (d) AsbA as a function of spermidine, or 
(e) AsbA as a function of citrate, (f) AsbA as a function of ATP. 
 
 
  
Figure 2-33. Live culture bioactivity Studies 
(a) BmcB against S. aureus (Newman), (b) BmcB against B. anthracis (Sterne 34F2), and (c) 
BmcA against S. typhimurium in iron-depleted (IDM) and iron-rich (IRM) media. 
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Figure 2-34. Phylogenetic trees  
(a) SbnE and (b) AsbA depicting potential secondary targets within microbial cells.   Both 
enzymes seem to share degrees of similarity to several enzymes, including adenylate-forming 
ones.  
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Substrate Vmax 
(µM/sec) 
Km (mM) Ki (µM) BmcA Inhibition Type 
SbnE in Staphyloferrin B Biosynthesis of S. aureus  
LDAP 0.054 37 210 Competitive 
Citrate  0.20 
 
6.9 
 
50 Competitive 
ATP 0.010 15 680 Competitive  
AsbA in Petrobactin Biosynthesis of B. anthracis 
Spermidine 0.13 
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170 Competitive 
Citrate 0.039 
 
10 
 
110 Competitive  
ATP  0.073 34 230 Competitive  
Table 2-4. Enzyme kinetics 
 
2.5 Materials and Methods 
General Experimental Procedures. Optical rotation measurements were obtained on a 
Perkin-Elmer 241 Polarimeter calibrated using a Rudolph Quartz Control Plate 
Calibration Standard at sodium D line (at +11.502°). UV spectra were obtained on a UV-
visible Molecular Devices SpectraMax M5 spectrophotometer using 1 mL cuvettes with 
1.0 cm path lengths at room temperature in solvent MeOH. IR spectra were obtained on a 
Perkin Elmer Spectrum BX FT-IR spectrometer. Spectrophotometric assays were 
performed on Molecular Devices SpectraMax M5 384 variable wavelength spectrometer. 
All NMR spectra were acquired on a Varian INOVA 500 MHz and a Varian INOVA 700 
MHz spectrometer at the NMR Facility, Department of Chemistry, University of 
Michigan. High-resolution APCIMS spectra were measured at the University of 
Michigan core facility in the Department of Chemistry using an Agilent 6520 Q-TOF 
mass spectrometer equipped with an Agilent 1290 HPLC system. RP-HPLC was 
performed using Waters Atlantis® Prep T3 OBD™ 5 µm 19 × 250 mm column and Luna 
5 µm C8(2) 100 Å, AXIA packed column and a solvent system of MeCN and H2O. The 
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LCMS analysis of HPLC fractions was performed on a Shimadzu 2010 EV APCI 
spectrometer.    
 
Biological Material. Streptomyces tempisquensis (Strain # 34946-N9) was isolated from 
marine sediments collected at Playa Grande mangrove, Costa Rica (collection permit R-
CM-INBio-30-2007). The procedure for the isolation of actinomycetes from these 
samples was previously described by Magarvey et al. (73). Maintenance and propagation 
of cultures were performed using standard media and protocols where 500 mg of wet 
sediment was diluted in 10 mL of sterile water and vortexed for 10 min.  Then, 1 mL of 
this suspension was applied directly to the top of the discontinuous sucrose gradient and 
centrifuged for 30 minutes at 300 x g.  500 µL of the 20%, 30%, and 40% layers were 
then plated to HVA agar supplemented with 10 µg/mL chlortetracycline, 25 µg/ml 
cyclohexamide, and 25 µg/ml of nalidixic acid.  The plates were then incubated at 28 °C 
for one month.  The colony was picked off the plate and streaked onto ISP2 agar until 
pure.  Seed cultures were grown in 17 mL dual position cap tubes containing 2 mL of 
ISP2 and grown for 4 days on a rotary shaker at 200 rpm.  The seed culture was then 
poured into a 250 mL baffled flask containing 100 mL of ISP2 and grown for 18 days on 
a rotary shaker at 200 rpm.  The culture was centrifuged at 4000 rpm for 10 min to 
remove the cells and 2 g of XAD16 resin (Sigma-Aldrich, St. Louis, Mo.) contained 
within a polypropylene mesh bag was added to the broth and incubated overnight on the 
rotary shaker.  The resin bag was removed and placed into 10 ml of MeOH followed by 
10 ml of acetone and 10 ml of ethyl acetate.  Each of the three fractions was dried in 
vacuo and reconstituted to a final concentration of 15 mg/mL in DMSO. 
 
Culture Maintenance and Fermentation. Seed cultures of 100 mL (×5) of ISP2 media 
(1% malt extract, 0.4% yeast extract, 0.4% dextrose, 3% NaCl) were inoculated with a 
loopful of vegetative cells from an oatmeal plate (6% oat meal, 1.25% agar, 3% NaCl) 
culture of Streptomyces tempisquensis and incubated with shaking (200 rpm) at 28 oC for 
5 days. A 25 mL portion of the seed cultures were transferred to a 2.8 L Fernbach flask 
containing 1.5 L of the ISP2 medium, and the 39L fermentation was carried out on a 
rotary shaker (200 rpm) at 28 °C for 18 days. After 14-18 days of growth, the cultures 
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were harvested by centrifugation.  The resulting cell free broth was subjected to solid 
phase extraction using 15 g of Amberlite XAD-16. The resin was then separated by 
filtration and subjected to organic extraction using MeOH: EtOAc (1:1).  
 
Isolation and Purification of Baulamycins A-B (6-7). The organic extracts concentrated 
under vacuum to afford the crude extracts (~10 g) obtained from 39 L culture. The crude 
extracts were dissolved in 100 mL of H2O and were subjected to a C18-silica gel column 
(20 × 2.6 cm, YMC Gel ODS-A, 12 nm, S-150 µm). The C-18 column was eluted with a 
stepwise gradient of H2O/ACN (100:0   0:100) to give nine fractions (Fr.1−Fr.8), which 
were concentrated in vacuo to yield fractionated organic materials, respectively. All eight 
fractions were assayed in the developed in vitro enzymatic assay at 10 and 1.0 ppm. The 
bio-active Fr.5 was further purified by RP-HPLC on a gradient of 50-90% ACN and was 
followed by UV/vis photodiode array detection at 210 nm to yield semi-pure compounds 
6 (10.3 mg) and 11 (6.4 mg). Compounds were again subjected to re-purification over 
RP-HPLC on isocratic condition of 59% ACN using C-8 column to get compounds 6 (3.6 
mg) and 7 (2.1 mg). 
 
Baulamycin A (6): Isolated as light yellow amorphous solid: [α]20D -10.3 (c 0.20, 
MeOH); IR (film) 3324, 3012, 2952, 2867, 1699, 1602, 1456, 1377, 1143 cm-1; UVmax 
(λ212 (log ε 3.24), 227 (log ε 2.93), and 280 (log ε 2.51). 
Baulamycin B (7): Isolated as light yellow amorphous solid: [α]20D -10.1 (c 0.20, 
MeOH); IR (film) 3321, 3016, 2941, 2873, 1702, 1602, 1456, 1365, 1141 cm-1; UVmax 
(λ) 212 (log ε 3.24), 227 (log ε 2.93), and 280 (log ε 2.51). 
 
Gene Cloning, Expression, and Purification of Enzymes.  The sbnE gene was PCR 
amplified from the genomic DNA of S. aureus (Newman).  The resulting PCR fragment 
was cloned into the ligation independent cloning (LIC) vector pMCSG7, containing an 
N-terminal His6 tag (74). Cloning of the construct containing the asbA gene into the C-
terminal His6 LIC vector pMCSG26 has been described previously (75). However, a 
mutation (L299P) was later discovered within the cloned asbA gene sequence.  The gene 
was transferred into pET28a and site directed mutatgenesis was used to revert the 
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sequence to wild type.  This reverted construct was utilized in dose response and kinetic 
studies.  The cloning of the asbB gene into the vector pET28b has been previously 
described (58). 
 
To obtain purified protein from constructs, recombinant E. coli BL21 (DE3)-Gold 
(Stratagene) cells containing the pRARE plasmid (Novagen) encoding tRNAs of rare 
codons were grown in terrific broth to an A600 nm of ~0.8 at 37°C and then cooled to 18°C 
for an overnight induction with 0.2 mM isopropyl β-D-1-thiogalactopyranoside.  
Harvested cell pellets were lysed by sonication in a buffer containing 40 mM imidazole, 
20 mM HEPES, 300 mM NaCl, 1 mM tris (2-carboxylethyl) phosphine (TCEP), 10% 
glycerol, a cocktail of protease inhibitors (EDTA-free Complete, Roche), and ~5 mg of 
lysing enzymes from Trichoderma harzianum (Sigma L1412).  The cell-free extract was 
collected by ultracentrifugation at 45,000 x g for 45 minutes.  The supernatant was 
subjected to Ni2+ affinity chromatography using a HiTrap™ Chelating HP column (GE 
healthcare) on a Fast-performance Liquid Chromatography system (FPLC system, 
Amersham Biosciences) with a linear gradient of 40-300 mM imidazole in 20 mM 
HEPES, 300 mM NaCl, 1 mM TCEP, and 10% glycerol.  Purified protein was dialyzed 
against 2 L of storage buffer containing 40 mM HEPES, 150 mM NaCl, 1 mM TCEP, 
and 10% glycerol at pH 8.  Protein was concentrated using Amicon Ultra centrifugal 
molecular weight cutoff filters (Millipore), flash frozen in liquid N2, and stored at -80°C 
until analysis.     
 
Natural Product Extract Library. At the time of screening, the natural product extract 
(NPE) library at the University of Michigan Center for Chemical Genomics contained 
~20,000 extracts.  Each extract in the library is derived from marine samples collected 
from all over the world, including Costa Rica, Panama, and Papua New Guinea.  Some of 
these samples are from isolated microbes (n=19055) while others were derived from 
field-collected biomass samples (“macrosamples,” n=800).  Previous work describes in 
detail how these extracts are prepared for the library (76).  
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 Assay Development and High-Throughput Screening. Fitness of assays for high 
throughput screening was determined using a Z factor statistical parameter (77), where p 
and n represent a positive control and negative control containing no enzyme and no 
inhibiting compound/extract, respectively: 𝑍 = 1− 3(𝜎! − 𝜎!)𝜇! − 𝜇!  
The NIS hydroxymate-formation assays were conducted as previously described (78). 
The NIS-tailored malachite green assays were modified from previously described 
protocols (61-63). Assays were performed in a 384-well plate format with a final volume 
of 40 µL. Enzymatic activity of both enzymes was found to be most uniform across clear 
polystyrene microplates produced by Greiner Bio-One (781185). For both assays, we 
sought conditions that enabled the use of low enzyme concentrations to facilitate optimal 
detection of any extracts containing low abundance biologically active compounds.  For 
the SbnE reactions, standard final conditions were 25 mM HEPES, pH 7.5, 5 mM MgCl2, 
100 µM ATP, 100 µM citrate, 100 µM L-DAP, 0.4 U/mL IPP, and 25 nM SbnE.  For 
AsbA reactions, standard final conditions were 20 mM HEPES, pH 7.5, 1 mM MgCl2, 
150 µM ATP, 80 µM citrate, 800 µM spermidine, 0.2667 U/mL IPP, and 100 nM AsbA.  
Reaction mixtures were split into two solutions: a substrate solution and an enzyme 
solution to initiate reactions (Figure S3A).  First, 30 µL of a substrate mix containing 
HEPES, MgCl2, ATP, citrate, the corresponding polyamine, and IPP was dispensed into 
384-well plates using a Multidrop (Thermo Fisher Scientific).  Compounds, natural 
product extracts, or DMSO vehicle controls were then added to wells using a high density 
replication tool on a Biomek FX liquid handler (Beckman Coulter).  To initiate the 
reactions, 10 µL of an enzyme solution containing HEPES, MgCl2, and purified SbnE or 
AsbA enzyme was added to the reactions using a Multidrop. For positive controls, an 
equal volume of a solution only possessing HEPES and MgCl2 was added.  Following 
incubation at room temperature (SbnE: 30 minutes; AsbA: 1 hour), 10 µL of quenching 
solution of 10 parts malachite green, 2.5 parts 7.5% (NH4)2MoO4, and 0.2 parts 11% 
tween-20 was added to reactions with the Multidrop.  Reactions were measured at A600 
nm using the Pherastar multimode plate reader (BMG Labtech) after incubating 15 
minutes at room temperature.  
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Dose-Response Assays against Purified Enzymes. A Mosquito X1 instrument (TTP 
Labtech) was utilized to dispense varying volumes of 50 mM isolated baulamycin 
compounds in DMSO onto clean 384 well microplates to make a final range of 
concentrations between 0 to 550 µM for SbnE and 0 to 1000 µM for AsbA and AsbB 
after a 40 µL reaction.  Spotted plates were stored at -20°C until analysis.   
 
Assays for SbnE and AsbA were carried out at the standard conditions used in screening 
(described above).  For AsbB reactions, final conditions were 20 mM HEPES, pH 7.5, 1 
mM MgCl2, 150 µM ATP, 80 µM citrate, 800 µM N1-(3,4-DHB)-N8-citryl-spermidine 
(6), 0.2667 U/mL IPP, and 100 nM AsbB.  Purification of 6 from B. anthracis Sterne 
34F2 ΔasbB culture supernatants was performed as described previously (58). After 
incubation at room temperature (SbnE: 30 minutes; AsbA/AsbB: 1 hour), reactions were 
quenched and incubated for 15 minutes as before.  Plates were read at A600 with a 
SpectraMax M5 microplate reader (Molecular Devices).  To conserve baulamycin 
compound, reactions were conducted in duplicate.  
 
Percent inhibition was calculated from raw absorbance data using a previously described 
formula (62) where p and n represent positive and negative controls respectively.   %  Inhibition =   100 Abs!"#$%& − Abs!!Abs!! − Abs!!    
 
Resulting data were fitted to the following standard log(inhibitor) versus normalized 
response model using GraphPad Prism version 5.0 (GraphPad Software).  This model 
demonstrated adequate fit, with R2 values for all SbnE and AsbA curves greater than 0.9.   
 𝑦 =    1001+ 10 !"#!"!"!! !"##$#%&'  
 
Enzyme Kinetic Assays. Reactions were a modification of previously described 
protocols (58, 65, 66, 79). Experiments were conducted by varying a single substrate and 
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holding remaining reaction components at a constant saturating level in the presence and 
absence of inhibitor. The MesG continuous pyrophosphate detection assay was carried 
out in 384-well microplates (Greiner Bio-One) at 40 µL final volumes in triplicate.  For 
both SbnE and AsbA reactions, constant standard conditions were 50 mM Tris, pH 8, 15 
mM MgCl2, 0.5 mM reducing agent (dithiothreitol for SbnE and TCEP for AsbA), 0.001 
units/µL PNP, 0.0004 units/µL IPP, 0.4 mM freshly prepared MesG, and 1 µM purified 
SbnE or AsbA enzyme.  SbnE kinetic reactions were conducted at fixed saturating 
concentrations of L-DAP (40 mM), citrate (10 mM), or ATP (12 mM) while AsbA 
kinetic reactions were conducted at fixed saturating concentrations of spermidine (40 
mM), citrate (20 mM), or ATP (12 mM).  The SbnE kinetic reactions with varied 
concentrations of citrate, L-DAP, or ATP were incubated for 8, 5, or 3 hours, 
respectively, before the addition of enzyme.  All AsbA reactions were incubated for 10 
minutes before initiation of the reaction with enzyme. For both sets of reactions, assays 
were tested at fixed concentrations of BmcA (0, 10, or 276.4 µM in DMSO) spotted with 
a Mosquito X1 instrument at varied concentrations of one substrate.  Measurements at 
A360 nm were taken every 30s over the course of 20 minutes using a SpectraMax plate 
reader (Molecular Devices).  The initial velocities under each set of reaction conditions 
were subsequently calculated using the slope function in Microsoft Excel.  Double-
reciprocal (Lineweaver-Bruk) plots of resulting kinetic data were then used to determine 
the mechanism of inhibition against each substrate.  The Ki values were determined from 
a replot of the slopes from the double-reciprocal plots versus concentration of BmcA (80, 
81).  
 
Dose-Response Assays against Microbial Cell Cultures. Strains were grown in LB-
Miller medium for iron-rich conditions and LB-Miller medium supplemented with the 
iron chelator 2,2'-bipyridyl (750 µM for S. aureus (Newman) and MRSA (USA 300) 
strains; 200 µM for the B. anthracis 34F2 strain) for iron-depleted conditions.  Pelleted 
cells from cultures grown to mid log phase (0.4 < OD600 < 0.6) in iron-rich conditions 
were washed 3x with medium supplemented with 2, 2'-bipyridyl to remove excess iron.  
Cells re-suspended in iron-depleted media were then used to inoculate fresh 96-well plate 
cultures at an OD600 of 0.003 in either iron-rich or iron-limited conditions.  Pure 
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baulamycins at concentrations designated in figures or vehicle controls containing an 
equal volume of DMSO were added to wells before incubation at 37°C, 200 rpm.  For 
dose response analysis, optical densities after 8 hours of inhibitor-treated (ODI) or 
DMSO-treated (ODC) cultures were fit to the following previously described (39) 
sigmoidal equation using GraphPad Prism software:  
 
ODI
ODC
  = 𝑏 +    (𝑎 − 𝑏)1+ [  I ]IC50 ! 
16S rDNA PCR Amplification, Cloning, and Sequencing. The genomic DNA of 
Streptomyces tempisquensis was extracted from 1 mL of culture using the Wizard® 
Genomic DNA Purification Kit (Promega A1120) per the manufacturer’s protocol. The 
16S rDNA was amplified from the isolated genomic DNA by PCR using the universal 
primers FC27 (5ʹ′-AGAGTTTGATCCTGGCTCAG-3ʹ′) and RC1492 (5ʹ′-
TACGGCTACCTTGTTACGACTT-3ʹ′) (82).  The PCR reaction mixtures were prepared 
according to the standard protocol described by GoTaq® Green Master Mix (Promega 
M7122).  A Bio-Rad iCycler thermocycler was used for template amplification with the 
following PCR cycle conditions: an initial denaturation step at 98°C for 30 s, followed by 
30 cycles of 95°C for 30 s, 50°C for 30 s, 72°C for 90 s, and a final extension of 72°C for 
7 min.  The PCR products were purified using the Wizard® SV Gel DNA Recovery Kit 
(Promega A9282). The purified PCR fragments were modified to add a 3’ A overhang 
using Taq DNA polymerase.  Ligation of the modified product into pGEM®-T Easy 
vector (Promega) was completed with T4 DNA Ligase (NEB M0202) according to the 
manufacturer’s standard protocol.  The resulting pGEM-16S rDNA construct was 
transformed into chemically competent E. coli DH-5α cells.  The transformation 
reactions were mixed with 40 µL of X-gal (20 mg/mL in DMSO) and 40 µL IPTG (100 
mM in sterile H2O) before plating on LB agar plates containing ampicillin (250 µg/mL).  
Plates were incubated overnight at 37oC for α-complementation. After incubation, single 
white colonies were used to inoculate LB media in sterile culture tubes (×6). All the tubes 
were incubated at 37oC, 250 rpm for overnight growth. Plasmid DNA was isolated from 
pelleted cells using the Wizard® SV Miniprep Kit (Promega A1460) and sequenced 
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using T7 and SP6 primers. The 16S sequence for S. tempisquensis has been given the 
GenBank accession number KF954543.  
 
Phylogenetic Analysis.  Phylogenetic analyses were conducted in GENEIOUS R6. 
Geneious version 1.8 (Biomatters). The evolutionary history was inferred using the 
Neighbor-Joining method. The bootstrap consensus tree inferred from 1000 replicates 
was taken to represent the evolutionary history of the taxa analyzed.  
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Chapter 3 
Understanding natural products from uncultured bacteria:  
Metagenomic analysis of the endosymbiont producer of a 
chemotherapeutic natural product 
 
3.1. Introduction 
Natural products are a critical source of pharmaceuticals and lead compounds in drug 
discovery efforts (83, 84).  Over the last several decades, scientists have isolated 
thousands of biologically active metabolites from terrestrial and marine macroorganisms, 
including plants, insects, and animals. Mounting evidence suggests that microbial 
symbionts may be the actual producers of most of these natural products (26, 27).  
 
Currently, the vast majority of drug-producing symbiotic microbes remain 
uncharacterized.  Most fall into the > 99% of bacterial species currently incapable of 
being cultured in the laboratory, hindering their study (26, 28).  Identifying these 
symbionts and understanding their genetic, biochemical, and metabolic characteristics is 
critical for advancing fundamental knowledge and potential applications. Many 
symbiont-derived secondary metabolites can only be isolated in low yields from their 
hosts, making large-scale production for pharmaceutical purposes unsustainable from 
both an economic and environmental perspective.  Although total synthesis can 
sometimes solve the supply problem, it can be costly and fails to address our 
understanding of the unique biosynthetic processes that are mediated by these elusive 
microbes (85). Sequencing and analysis of symbiont genomes could provide insight into 
the lifestyles of these elusive bacteria, illuminate possible host-free cultivation methods, 
and provide a route to economical and sustainable large-scale production with the 
opportunity for genetic manipulation to produce novel drug analogues.  
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Figure 3-1. Mangrove tunicates the tetrahydroisoquinoline natural products. 
A.) Tunicate colonies growing on the root of a mangrove tree in the Florida Keys. B.) The 
metagenomic DNA from four individual tunics (zooids) from two colonies was isolated and 
sequenced.  C.) The chemotherapeutic compound ET-743 (1) and three natural products from 
cultured bacteria that share a similar tetrahydroisoquinoline core.  
 
The chemotherapeutic compound ET-743 (1, Yondelis, Trabectedin) is one of the most 
important natural products suspected to be of symbiotic origin.  Isolated directly from the 
mangrove tunicate Ecteinascidia turbinata (Figure 3-1AB), the biological activity of the 
drug against cancer cells has inspired over 40 years of research (86, 87).  Currently, ET-
743 is clinically approved in Europe against soft tissue sarcoma and relapsed ovarian 
cancer and is currently in phase III trials as an anticancer therapeutic in the United States 
(88).    
 
The tetrahydroisoquinoline alkaloid natural products saframycin A (2), saframycin Mx1 
(3) and safracin (4) are derived from three distinct cultured bacteria and are structurally 
similar to ET-743, supporting a bacterial origin for the drug (Figure 3-1C).  Studies of 
the mangrove tunicate over a decade ago identified the potential intracellular 
Gammaproteobacterium Candidatus Endoecteinascida frumentensis to be the most 
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prevalent member of the host microbial consortium (89, 90) and the only bacterial species 
consistently associated with tunicates in both the Mediterranean and Caribbean seas (89).  
A metagenomically-derived contig containing a partial ET-743 biosynthetic gene cluster 
was later indirectly linked to a separate contig bearing the 16S rRNA gene sequence for 
Ca. E. frumentensis through analysis of %G+C content and codon usage (91).  
Cultivation of the producing bacterium has so far been unsuccessful (89, 90), and 
aquaculture (92) of the host tunicate and total synthesis (93) have also failed to provide 
sustainable access to the drug for clinical applications.  ET-743 is therefore currently 
generated by a lengthy semisynthetic process starting from fermentation-derived 
cyanosafracin B (94).   
 
In this study, we utilized next generation sequencing technologies to expand and 
complete the biosynthetic gene cluster and uncover the complete genome of the 
microorganism responsible for ET-743 production.  Analysis of phylogenetic markers 
and protein coding genes suggests that the microbe belongs to a novel family of 
Gammaproteobacteria.  In-depth genomic analysis also provides initial insights into the 
endosymbiotic lifestyle of Ca. E. frumentensis, the ecological role of its sole secondary 
metabolic pathway, and key information that may provide access to host-cell free growth 
in the laboratory.   
 
3.2 Results and Discussion 
3.2.1 Overview of Samples and Dataset.  
The colonies of E. turbinata consist of thick bundles of individual zooids connected by a 
network of stolons that enable adherence of the animal to a stable surface (92). Our 
laboratory previously isolated metagenomic DNA from individual zooids and uncovered 
a 35 kb gene cluster responsible for ET-743 biosynthesis using 454 pyrosequencing (91). 
In the present study, we isolated additional metagenomic DNA from four zooids obtained 
from two colonies (Figure 3-5 in Supplemental Information [SI]).  We shotgun 
sequenced the resulting DNA samples using Illumina HiSeq technology and assembled 
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the data into contigs.  The four zooids provided metagenome datasets each containing 
over 800 Mbp of sequence (Table 3- 2 in SI).  
 
We assigned the assembled contigs to taxonomic bins using tetranucleotide frequency 
with emergent self-organizing maps (tetra-ESOM) as previously described (Figure 3-6 in 
SI) (95).  Each of the four metagenomic samples possessed a single bin containing both 
the previously identified partial ET-743 biosynthetic gene cluster and the 16S rRNA gene 
for Ca. E. frumentensis (Table 3-2 in SI). The four bins containing the ET-743 
producing microorganism were further assembled into a consensus genome containing 
three contigs.  PCR amplification closed a 200 bp gap between two of the contigs to 
create a 630 kb scaffold.  Additional PCR amplification closed a final 1.5 kb gap in the 
scaffold to create the closed genome for Ca. E. frumentensis (Figure 3-2, Table 3-1, and 
Figure 3-5 in SI). 
 
Figure 3-2. A circular map of the closed genome of Candidatus E. frumentensis.   
The outermost circle displays protein-coding genes assigned to Pfam categories (see key). The 
dark grey and light grey circles display protein-coding genes on the plus strand and minus 
strands, respectively.  The fourth circle depicts a histogram of G+C content throughout the 
genome.  The innermost circle represents ET-743 biosynthetic genes.  Genes previously identified 
are depicted in light red while putative new genes are shown in dark red.  
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The coverage depth for the endosymbiotic genome averaged 721x between the four 
samples (Table 3-3 in SI).  However, one contig that consistently binned with ET-743 
producer, and that was retrieved in all four samples, was not incorporated into the 
genome. This much smaller ~18 kb contig encodes a DNA primase and two protein-
coding genes with ambiguous functions that repeat throughout the stretch of the 
sequence.  Unlike the circular genome, the shorter contig has a coverage depth of only  
~74x and reads could not be mapped to the sequence with confidence. The excluded 
contig may be an extrachromosomal element that is present in only a subset of the Ca. E. 
frumentensis population, or an artifact of the assembly and binning process. Given that 
the rest of the genome was closed and displayed even and deep coverage, we focused our 
analysis on the closed Ca. E. frumentensis genome in this study.  
 
Very few other genomic bins were detected in the metagenomic datasets, despite prior 
evidence that the tunicate housed a complex microbial consortium (Table 3-2 in SI) (90, 
91). However, previous studies indicated Ca. E. frumentensis was one of the most 
abundant species in the consortium (89-91) and the only microorganism found to be 
consistently associated with the tunicate host in both the Mediterranean and Caribbean 
marine habitats (89). Further, metagenomic assembly of the symbiont population was 
likely facilitated due to its low genomic diversity compared to populations that are non-
specifically associated. Thus, it is likely that the eukaryotic host and Ca. E. frumentensis 
monopolized the sequencing data, especially the large assembled contigs, despite the 
presence of a complex but lower abundance microbial community.  The only other 
notable bin after tetra-ESOM was a cyanobacterium from the order Oscillatoriales that 
was present in two of the four metagenomic DNA samples (Table 3-2 and Figure 3-6 in 
SI).  
 
3.2.2 Genome Reduction in the Symbiont.  
Previous in situ hybridization analysis provided an initial indication that Ca. E. 
frumentensis could be a bacterial endosymbiont (90).  Assembly and analysis of the 
microbe’s complete genome provides further convincing evidence of an intracellular 
lifestyle and long-term evolution with the tunicate host, E. turbinata.  Ca. E. frumentensis 
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possesses many of the hallmarks of genome reduction, which is thought to be driven by a 
small bacterial population size and an inherent deletion bias (96-98).  The circular 
genome for Ca. E. frumentensis is quite small, totaling only 631,345 bp (Figure 3-2). 
The small size of the genome rivals those of the model obligate endosymbionts Buchnera 
aphidicola in aphids and Wigglesworthia glossinidia in tsetse flies (Table 3-4 in SI).  
The functions maintained by Ca. E. frumentensis are also consistent with the minimal 
gene sets observed in these and other obligate symbionts (Figure 3-7 in SI).  For 
example, Ca. E. frumentensis appears to have lost a number of genes involved in DNA 
replication and repair mechanisms (Figure 3-7 in SI). The loss of DNA repair 
mechanisms is thought to be a crucial turning point during the evolution of an 
endosymbiont (96, 99).  Loss of these genes is frequently accompanied by increased 
mutation rates, an A+T DNA sequence bias, and the loss of additional nonessential genes.  
 
Detail Candidatus E. frumentensis 
Genome Size (bp) 631,345 
GC Content (%)  
     Total 23.3 
     Coding Regions 24.2 
     Noncoding Regions 12.7 
Coding Density (%) 90.7 
Intergenic Pseudogenes 10 
Protein-coding genes 585 
     With functional annotation 556 (95.0%) 
     With ambiguous function 29 (4.6%) 
rRNA genes 3 
tRNA genes 32 
 
Table 3-1. General features of the Candidatus E. frumentensis genome. 
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Indeed, the exceptionally low total G+C content (23.3%) of Ca. E. frumentensis genomic 
DNA supports a mutational bias and an obligate endosymbiotic lifestyle.  The G+C 
content disparity between the coding (24.2%) and noncoding (12.7%) regions of the 
genome (Table 3-1) further exemplifies this bias.  Bacterial lineages that only recently 
became restricted to a host organism also often have higher numbers of pseudogenes 
within these noncoding regions and a consequently low overall coding density (100).  
However, as bacteria continue to co-evolve with their hosts, pseudogenes gradually 
shrink and become unrecognizable through deletions while genomes become more 
compact (97, 101, 102). The noncoding regions of the Ca. E. frumentensis genome have 
only 10 pseudogenes whose predicted translation products show amino acid sequence 
similarity to known proteins (Table 3-5 in SI).  The genome also has a higher overall 
coding density of 90.7% (Table 3-1), similar to B. aphidicola, W. glossinidia, and other 
obligate endosymbionts that co-evolved with their hosts along the order of millions of 
years (99, 103, 104). Taken together, these data provide strong support that Ca. E. 
frumentensis is an obligate endosymbiont that has undergone long-term co-evolution with 
the tunicate host, E. turbinata.  
3.2.3 Phylogenetic analysis and novelty of Ca. E. frumentensis.  
The genome of Ca. E. frumentensis also appears to be remarkably distinct from other 
studied microorganisms. Analysis of conserved markers provided the first evidence that 
Ca. E. frumentensis may be phylogentically distant from characterized bacterial species. 
The closest homologues for genes encoding the 16S rRNA gene, rpoB, and recA had 
86.1%, 69.0%, and 74.8% sequence identities respectively (Figure 3-8 in SI).   
 
Phylogenetic markers can be useful for microorganisms that have many well-studied and 
cultured close relatives. However, in microorganisms with fewer obvious relatives, the 
average amino acid identity (AAI) of shared genes can be more revealing (105).  To 
further explore the phylogenetic novelty of Ca. E. frumentensis, we compared the AAI 
and 16S rRNA gene of the microorganism to other bacterial species selected from a 
taxonomic profile of the Ca. E. frumentensis genome. This analysis confirmed that Ca. E. 
frumentensis is taxonomically distinct from many of its originally predicted relatives and 
likely represents a new family of Gammaproteobacteria (Figure 3-9 in SI) (106). 
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Figure 3-3. Overview of the metabolism of Ca. E. frumentensis deduced from genomic 
analysis.  
Reaction products depicted in red have either missing or partially missing biosynthetic pathways. 
ACP, acyl carrier protein; AICAR, 5-Aminoimidazole carboxamide ribonucleotide; CoA, 
coenzyme A; DHAP, Dihydroxyacetone phosphate; DHF, dihydrofolate; DMAPP, Dimethylallyl 
pyrophosphate; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; IMP, inosine 
monophosphate; NAD, Nicotinamide adenine dinucleotide; PRPP, Phosphoribosyl 
pyrophosphate; THF, tetrahydrofolate; UMP, uridine monophosphate.  
 
3.2.4 Primary Metabolism.  
Central metabolism and carbon sources. Analysis of primary metabolic pathways 
(Figure 3-3) provided further insight into the lifestyle of the taxonomically distinct 
endosymbiont Ca. E frumentenes and its relationship with the host tunicate. Despite the 
small size of the genome, Ca. E. frumentensis possesses portions of all three components 
of central metabolism.  The tricarboxylic acid cycle (TCA cycle) is intact as is most of 
the non-oxidative branch of the pentose phosphate pathway.  The symbiont also has the 
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majority of the genes involved in the glycolytic pathway and gluconeogenesis.  
Interestingly, the genome is devoid of any genes encoding enzymes involved in early 
glucose catabolism (Figure 3-3). This is surprising since glucose is the preferred carbon 
source for many bacteria (107).  However, the symbiont may use alternative sugar 
sources from the host for energy.  The genome encodes two sugar phosphate transporters 
and enzymes for the remainder of the glycolytic pathway (Figure 3-3).  Sugar phosphates 
can be important carbon sources for intracellular pathogens and endosymbionts, 
especially those present in the host cytosol (108).  The symbiont may import sugar 
phosphates from the host, including fructose-1-phosphate or more advanced sugar 
phosphate intermediates in the glycolytic or pentose phosphate pathways.  
 
Electron transport chain. The symbiont genome encodes a complete electron transport 
chain and an F-type ATPase (Figure 3-3).  The respiratory chain likely obtains electrons 
from succinate and NADH produced from the TCA cycle to generate an electrochemical 
gradient and produce ATP. Interestingly, cytochrome bo3 (encoded by cyoABCDE) is the 
terminal cytochrome oxidase in the respiratory chain (Figure 3-3). This indicates that the 
symbiont is capable of growth under high oxygen tension, similar to endosymbionts in 
the genera Buchnera and Wigglesworthia (109, 110).  Conversely, intracellular pathogens 
from the genera Legionella, Brucella, Chlamydia, Rickettsia, and Coxiella are thought to 
rely on microaerophilic metabolism during intracellular growth (111, 112). 
 
Amino acid and cofactor metabolism. Similar to most obligate endosymbionts and many 
intracellular pathogens, Ca. E. frumentensis seems to lack a number of genes involved in 
the biosynthesis of key amino acids and cofactors (Figure 3-3).  Genes encoding intact 
pathways for de novo biosynthesis of asparagine, aspartic acid, glutamine, and glutamic 
acid are present, but pathways for the remaining 16 amino acids are either partially or 
completely missing (Figure 3-3).  The symbiont likely obtains many of these missing 
amino acids from the tunicate host.  Indeed, the Ca. E. frumentensis genome encodes 
specific transporters for methionine, tryptophan, and tyrosine along with an additional 
putative amino acid transporter (Figure 3-3).  The symbiont could also import pathway 
intermediates to complete production of some amino acids possessing partial biosynthetic 
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pathways (e.g. glycine, serine, alanine, proline, and arginine). 
 
Ca. E. frumentensis also lacks many genes involved in coenzyme A (CoA) biosynthesis 
(Figure 3-3). Genes encoding enzymes responsible for production of CoA precursors are 
absent.  However, later steps of the pathway are intact, suggesting the symbiont is 
capable of CoA biosynthesis from host-derived pantotheine, β-alanine, cysteine, or 
another CoA precursor.  The inability to produce CoA de novo is relatively common in 
endosymbionts and bacterial pathogens (113).  The obligate endosymbiont Buchnera 
aphidcola, for example, works collaboratively with its aphid host to biosynthesize CoA 
(109).  Similarly, intracellular pathogens from the genera Mycoplasma, Rickettsia, and 
Chlamydia have incomplete pathways for the coenzyme and often need media 
supplements for host-cell free growth or pathogenicity (114-116).  Only a selection of 
these species have transporters suspected to facilitate CoA and precursor environmental 
uptake (117).  It is therefore not surprising that Ca. E. frumentensis lacks transporter 
candidates for this role. 
 
Membranes and transport. The Ca. E. frumentensis genome contains gene sets for the 
biosynthesis of lipids commonly incorporated into bacterial membranes, including 
phosphatidylethanolamine, cardiolipin, and phosphatidylglycerol (Figure 3-3).  
However, the endosymbiont possess an incomplete gene set for peptidoglycan 
biosynthesis (Figure 3-3 and Figure 3-7 in SI). The vast majority of bacteria incorporate 
some level of peptidoglycan into their cell walls, but peptidoglycan is absent in a few 
bacteria, including Mycoplasma species, Planctomyces, and Rickettsia.  Like Ca. E. 
frumentensis, some insect endosymbionts may also lack the ability to make 
peptidoglycan; B. aphidicola BCc (118), Carsonella ruddii (119), and Ca. Sulcia 
muelleri (120) are missing the majority of genes involved in the biosynthesis of 
peptidoglycan. Only dacA, the gene responsible for the final processing step in 
peptidoglycan biosynthesis, is present in the Ca. E. frumentensis genome (Figure 3-3 and 
Figure 3-7 in SI).  
 
In addition to peptidoglycan, Ca. E. frumentensis also seems to lack the genes 
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responsible for biosynthesizing and incorporating lipopolysaccharides in its outer 
membrane (Figure 3-3 and Figure 3-7 in SI).  Lipid A biosynthetic genes are also absent 
from many endosymbionts, including Baumannia cicadellinicola and Buchnera species 
(98, 120).  The loss of lipid A from these endosymbionts could be an evolutionary result 
of its high toxicity to most eukaryotic hosts.  
 
Despite its unusual membrane composition, the endosymbiont still has considerable 
genomic potential for metabolite transport. The genome encodes 71 genes putatively 
linked to transporter function.  Although the specificity of many of these transporters is 
difficult to assess, others are well annotated. In addition to amino acid and sugar 
phosphate transporters, the genome also encodes membrane proteins that may target 
inorganic phosphate, iron, and potassium along with sodium-calcium and sodium-
hydrogen antiporters  (Figure 3-3).  
 
Ca. E. frumentensis also has genes encoding a near intact Sec protein translocation 
pathway and enzymes involved in the recognition of signal peptides (Figure 3-3).  Only 
the nonessential components SecG and SecM appear to be absent.  The ABC transporter 
responsible for localization of lipoproteins to the periplasmic surface of the outer 
membrane (LolCDE), as well as essential components involved in inserting β-barrel 
proteins into the outer membrane (BamADE), are also present. 
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Figure 3-4. Completion of the ET-743 biosynthetic gene cluster.   
A.) New ET-743 biosynthetic genes were identified upstream and downstream of the original ET-
743 biosynthetic gene cluster (outlined in black).  Gene products are classified as pyruvate 
dehydrogenases, enzymes of unknown function, transport proteins, regulatory and primary 
metabolism enzymes, flavoenzymes, methyltransferases, acetyltransferases, fatty acid 
biosynthetic enzymes, DNA processing enzymes, nonribosomal peptide synthetases, and 
hydroxylases.  B.) An updated proposed biosynthetic pathway for ET-743.   
 
3.2.5 Secondary Metabolism.  
We previously identified a 35 kb contig containing many of the genes involved in the 
biosynthesis of the chemotherapeutic natural product ET-743 (91).  However, close 
examination of ET-743, its previously isolated precursors (87), and other well-studied 
tetrahydroisoquinoline natural products (121-124) led us to suspect that we were still 
missing a number of key biosynthetic genes (91).  Expanding the 35 kb gene cluster to a 
complete genome for Ca. E. frumentensis has enabled us to identify many of these 
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previously missing key genes and improved our understanding of ET-743 biosynthesis.  
Key genes involved in production of the chemotherapeutic drug span over 173 kb of the 
small 631 kb genome (Figure 3-2).  Biosynthetic genes are split into three distinct 
clusters within this expansive genomic range (Figure 3-4A, Table 3-6 in SI).  Newly 
detected gene products include the acetyltransferase EtuY and EtuM4, likely involved in 
acetylation and N-methylation to make 7 and ET-597 (9) respectively.  We also identified 
three new flavoproteins in addition to the FAD-dependent monooxygenase (EtuO1) 
contained within the original ET-743 biosynthetic gene cluster (91).   
We additionally identified a gene encoding the E3 component of the pyruvate 
dehydrogenase complex (EtuP3, Figure 3-4).  The reactions catalyzed by this enzyme 
system typically provide the TCA cycle with acetyl-CoA (125).  However, the primary 
metabolic enzymes were recently shown to also contribute to the biosynthesis of 
quniocarcin and naphtyridinomycin natural products (126). The enzyme complex can 
work with an acyl carrier protein (ACP) to provide a glycolicacyl-S-ACP extender unit 
(5) for a non-ribosomal peptide synthetase (NRPS).  Both of these gene clusters in 
addition to SF-1739 (124) and the original ET-743 (91) biosynthetic gene cluster contain 
the E1 and E2 components for the enzyme complex.  Although the E3 component has 
been absent in previously studied clusters, purified exogenous E3 does seem necessary 
for complete product conversion (126).  The presence of the E3 component in Ca. E. 
frumentensis and its proximity to other ET-743 biosynthetic genes further exemplifies its 
importance in the biosynthesis of tetrahydroisoquinoline natural products.   
 
Another genomic feature that may set the ET-743 cluster apart from other natural 
products is the placement of the ACP that operates with the pyruvate dehydrogenase 
complex.  The ACP is located in the main biosynthetic gene clusters for quinocarcin, 
naphtyridinomycin, and SF-1739.  However, the only ACP in the entire Ca. E. 
frumentensis genome is located within a fatty acid biosynthetic cluster 61 kb downstream 
of the original ET-743 gene cluster (EtuF9, Figure 3-4A). The location of the ACP and 
the presence of other fatty acid biosynthetic genes (EtuF1 and EtuF2) within the central 
ET-743 biosynthetic gene cluster further supports potential interaction between primary 
and secondary metabolism during ET-743 biosynthesis.  This ACP most likely works in 
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concert with EtuP1, EtuP2, and EtuP3 to provide the glycolicacyl-S-ACP extender unit 
(5) to EtuA1 (Figure 3-4B).   
 
Despite these new discoveries, we may still be missing some genes involved in ET-743 
biosynthesis.  For example, gene candidates for enzymes that catalyze formation of the 
thioether ring (8) and transamination to make ET-596 (10) remain to be identified.  We 
cannot rule out that these genes may be located elsewhere in the Ca. E. frumentensis 
genome or that the microbe works together with its host to complete construction of the 
chemotherapeutic compound. 
 
Although not included within the ET-743 gene cluster, the Ca. E. frumentensis genome 
also contains several genes found within the biosynthetic gene clusters of other 
tetrahydroisoquinoline natural products.  For example, the gene encoding the excision 
nuclease subunit UvrA is found within the saframycin A, and SF-1739, and quinocarcin 
gene clusters, perhaps playing a role in repairing damage induced by these potent natural 
products.  However, the gene in the Ca. E. frumentensis genome is located several 
hundred base pairs upstream from the original ET-743 gene cluster.  The saframycin A 
gene cluster also contains a complete gene set for the recycling of S-adenosyl methionine 
(SAM), a coenzyme essential for methyltransferase activity during the biosynthesis of all 
tetrahydroisoquinoline natural products.  The complete gene set for the recycling system 
is still present in the Ca. E. frumentensis genome, but the genes are located both upstream 
and downstream of the original gene cluster. 
 
The semi-dispersed nature of ET-743 biosynthetic genes is notable as microbial 
secondary metabolite systems are typically tightly clustered in bacteria with clearly 
identifiable boundaries (127, 128). However, genes involved in ET-743 biosynthesis are 
located in different points throughout the genome, interspersed with genes involved in 
primary metabolism (Figure 3-4). The fragmented nature of Ca. E. frumentensis 
secondary metabolism could be a consequence of horizontal gene transfer (129) and co-
regulation of gene expression within operons (130), which are two important forces 
thought to encourage selection and formation of gene clusters. However, the 
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endosymbiont lifestyle provides few opportunities for horizontal gene transfer, and 
regulatory mechanisms are often among the first genetic elements lost during genome 
reduction (96, 98).  The lack of selective pressure to retain clusters is thought to 
contribute to fragmentation of biosynthetic genes in other endosymbionts (131), and 
likely also plays a role in the organization of genes involved in ET-743 production.   
 
Analysis of the Ca. E. frumentensis genome has also improved our understanding of the 
importance of ET-743 biosynthesis in the relationship between the endosymbiont and the 
tunicate host, E. turbinata.  In long-term co-evolution, bacterial genes that are useful to 
the host are retained despite ongoing genome erosion (96, 98).  The survival of ET-743 
biosynthetic genes despite clear evidence of extreme genome reduction is indicative of an 
important role for the secondary metabolite to the host.  A query of the endosymbiont 
genome against the full complement of bioinformatics tools (e.g. antiSMASH 2.0 (132), 
NP.searcher (133), CLUSEAN (134), BAGEL3 (135), and 2metdb (136)) revealed that 
ET-743 was the only natural product gene cluster found within genome, further 
exemplifying its ecological value to the tunicate.  Adult ascidians such as E. turbinata are 
sessile marine invertebrates with soft-bodies, making them particularly vulnerable to 
predation.  Their large larvae are released during daylight hours, making them similarly 
susceptible to predators.  The secondary metabolite ET-743 could serve as a defense 
mechanism for the host.  Many other ascidians and sponges are thought to produce 
secondary metabolites and inorganic acids that make them unpalatable to predators (137-
139).  Indeed, ecological studies have already demonstrated that taste and orange coloring 
of larvae from E. turbinata protects the animal against predators (137, 140).  If ET-743 is 
the chemical deterrent responsible for protecting the host, it provides a driving force to 
assure ET-743 gene cluster survival despite millions of years of genome reduction.    
3.3 Conclusions 
We have assembled a complete genome for Ca. E. frumentensis, an endosymbiont 
responsible for production of the chemotherapeutic drug ET-743.  Microbial symbionts 
like Ca. E. frumentensis have long been thought to be the source of many natural 
products isolated from terrestrial and marine invertebrates.  However, very little is known 
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about the majority of these microbes due to our current inability to culture them in the 
laboratory.  
 
The complete genome of Ca. E. frumentensis has enriched our understanding of ET-743 
biosynthesis.  The expanded ET-743 gene cluster will enable future biochemical studies 
to confirm the roles of individual enzymes.  A better understanding of its biosynthesis 
can facilitate future in vitro and heterologous expression efforts to engineer sustainable 
production of the drug and related analogues. Analysis of the complete genome has also 
highlighted the importance of ET-743 to the host-symbiont relationship.  The lack of 
genomic evidence for other secondary metabolites, the survival of the gene cluster 
despite extreme genome reduction, and the cluster’s dispersal across the small genome 
suggests the microbe has become specialized for production of the drug.  The 
chemotherapeutic natural product is therefore likely crucial to the microorganism’s 
relationship with the tunicate host and its continued survival.  This is intriguing since 
secondary metabolites are traditionally thought to be nonessential for microbial life (141) 
despite their prevalence in microbial genomes (142) and ability to confer competitive 
advantages (143).  However, improved sequencing technologies and metagenomic 
pipelines are now permit more detailed studies of genomes undergoing reduction.  Full 
genome studies on the endosymbionts found in macroorganisms like bugs (144), 
tunicates (131, 145), or even fungi (146, 147) provide increasing evidence that natural 
products may sometimes play essential roles.  When these secondary metabolites benefit 
a host organism, their preservation may ensure a microorganism’s survival and even help 
guide coevolution with a host. The drastically reduced genome of Ca. E. frumentensis 
presented here further supports this theory.   
 
The pharmaceutical significance of ET-743 also demonstrates the potential potency of 
endosymbiont natural products.  A better understanding of symbiont genomes along with 
their primary and secondary metabolism could provide new routes to economical and 
sustainable large-scale production of bioactive natural products.  Analysis of the 
drastically reduced genome of Ca. E. frumentensis provides unique insight into the 
microorganism’s lifestyle and clues to possible host-free cultivation.  Previous attempts 
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to grow the microorganism in the laboratory were unsuccessful. However, our ability to 
culture elusive microorganisms is continually improving.  Recent advances in host-cell 
free growth of Coxiella burnetii (111) or the facultative symbionts Burkholderia spp., 
Rhodococcus rhodnii, and Wolbachia spp. (148) provide hope that the right growing 
conditions and techniques can provide access to the uncultured majority of bacteria.  
Genome analysis in particular has proven a powerful method to pinpoint nutrient and 
oxygen requirements for microbial growth (29, 111, 148). The loss of key primary 
metabolic pathways in Ca. E. frumentensis suggests that the microorganism could not 
live independently of the host using standard media and cultivation techniques.  The loss 
of genes involved in amino acid, coenzyme A, and glucose biosynthesis indicates that 
media enhanced with nutrients, cofactors, and alternative carbon sources may be 
necessary. However, genomic evidence for aerobic respiration and transporters for key 
metabolites provide hope that the right environmental conditions could one day lead to 
host-cell free growth.  
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3.4 Supplemental Information 
 
Figure 3-5. Origin of the four metagenomic DNA samples used to compile the consensus 
microbial genome of the ET-743 producer.   
The metagenomic DNA from zooids isolated from two separate tunicate colonies was sequenced. 
Bins corresponding to the ET-743 producer in each metagenomic dataset were combined to create 
a consensus genome.  
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Figure 3-6. An Emergent Self Organized Map of one of the four metagenomic DNA samples 
(IMG Submission ID 21664) from Ecteinascidia turbinata.   
Each data point represents a 5-kb sequence window, generated computationally from assembled 
contigs. Green data points are from unidentified contigs putatively assigned to the eukaryotic 
host. Data points shown in purple are from the Candidatus E. frumentensis bin, with circled data 
points contigs containing the 16S rRNA gene for E. frumentensis and the ET-743 biosynthetic 
gene cluster.  Those in red are from a cyanobacterium present in only two of the four samples 
(IMG Submission IDs 21664 and 19872). The background represents Euclidean distance of 
tetranucleotide frequencies between data points; gray and dark colors indicate larger distances, 
which are used to visualize the borders between genomic bins.  Borders defined for Ca. E. 
frumentensis and the Cyanobacterium are outlined in blue.  Clustered data points in yellow and 
dark blue represent bins from unknown bacteria.        
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Figure 3-7. The gene content of drastically reduced genomes.  
Shaded boxes represent the presence of a gene in the genome while white boxes represent its 
absence.  The minimal gene content of Ca. E. frumentensis more closely resembles the reduced 
obligate symbiont genomes of B. aphidicola (NC_011834) and W. glossinidia (CP003315) than 
the intracellular pathogen C. Burnetii (NC_011528) or the free-living microorganisms F. 
hongknongensis (GCA_000379445.1) and E. coli (NC 000913). 
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Figure 3-8. Phylogenetic reconstruction using conserved markers. 
Reconstruction of A. 16S rRNA gene, B. RpoB, and C. RecA first suggested that Ca. E. 
frumentensis might have a novel taxonomic rank higher than the species level.  Genes analyzed in 
this study for Ca. E. frumentensis are depicted in bold.  The sequence identity between listed 
genes and the corresponding gene in Ca. E. frumentensis is also included. Branch labels on the 
bootstrapped trees represent consensus support (%).   
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Figure 3-9. Relatedness between the 16S rRNA gene and the average amino acid identity 
(AAI) for Ca. E. frumentensis and similar microorganisms.  
Previously described taxonomic thresholds for phylum, class, order, family, genus (106), and 
species are shown in dotted lines.  Genomes were selected based on phylogenetic analysis of 
conserved genes and the taxonomic profile of the bin of the ET-743 producer.  Genomes for the 
listed P. fluorescens, S. lavendulae, and M. xanthus strains were included because similar strains 
are associated with the tetrahydroisoquinoline natural products safracin, saframycin A, and 
saframycin Mx1 respectively.    
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Table 3-2. An overview of the four metagenomic DNA sequence datasets isolated from 
Ecteinascidia turbinata.   
A single bin containing the ET-743 biosynthetic gene cluster and the 16S rRNA gene for Ca. E. 
frumentensis was present in every metagenomic sample.  Sample 19872 and 21664 also contained 
a bin with an rRNA marker for an Oscillatoriales species.  Sample 21664 contained an additional 
prokaryotic bin from an unknown microorganism.  
 
 
 
 
 
 
Metagenome Detail 15233 15306 19872 21664 
Total Assembled Bases 808,986,041 839,356,773 847,549,657 837,783,164 
Longest Sequence 97,417 391,789 163,783 171,962 
Shortest Sequence 200 200 200 200 
Total Genes 3,184,772 3,930,810 4,966,920 2,910,719 
16S rRNA genes 13 8 13 19 
Bins with rRNA marker 1 1 2 3 
Candidatus E. frumentensis 
 Bin Detail 
15233 15306 19872 21664 
Total Sequences 24 5 13 7 
Total Bases 662,683 636,675 635,600 635,519 
Longest Sequence 40,233 391,789 87,220 167,454 
Mean Length 27,612 127,335 48,892 90.503 
N50 40,233 391,789 87,220 167,454 
Shortest Sequence 4,464 7,967 4,125 4,268 
Estimated Completeness  100% 100% 100% 100% 
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Sample Genome Coverage Discarded Contig Coverage 
Sample 15233 1619.4783 121.71451 
Sample 15306 232.2210 34.82700 
Sample 19872 700.9010 85.40445 
Sample 21664 331.3278 54.26337 
Average 720.9820 74.05233 
 
Table 3-3. Coverage comparison between the complete Ca. E. frumentensis genome and the 
discarded contig. 
The consistently lower coverage for the ~18 kb contig that binned with the ET-743 producer 
caused us to exclude it from our analysis.   
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Table 3-4. An overview of the differences in genomes of endosymbionts, intracellular 
pathogens, and free-living microorganisms.  
The features of the draft genome of Ca. E. frumentensis correspond with those of obligate 
endosymbionts.  
 
 
 
 
Detail Buchnera 
aphidicola 
Wigglesworthia 
glossinidia 
Coxiella 
brunetii 
Francisella 
novicida 
 
Fangia 
hongkongensis 
Gold ID Ga0028046 Gp0000669 Ga0028449 Ga0028838 Ga0025332 
Genome Size (Mbp) 0.642 0.703 2.10 1.95 2.95 
Scaffolds 1 1 + p 1 + p 1 37 
GC Content 26.29 22.48 42.62 32.32 37.94 
Coding Density (%) 86.53 88.50 77.71 90.96 91.42 
Protein-coding genes 553 617 1,947 1,854 2,757 
    With functional 
     annotation 
529 131 1,231 1,339 1,971 
    With ambiguous 
     function 
24 486 716 515 786 
rRNA genes 3 6 3 10 15 
tRNA genes 32 34 42 38 38 
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Table 3-5. Pseudogenes identified in the noncoding regions of the Ca. E. frumentensis 
genome.  
 
 
 
 
 
 
 
 
 
 
Possible Former Gene Product Coordinates 
Start End 
Preprotein translocase subunit secY 28,854 29,134 
Peptide chain release factor 2 194,322 194,757 
4Fe-4S ferredoxin 232,151 233,405 
FAD-linked oxidoreducatse 233,604 234,101 
tRNA pseudouridine synthase B 279,113 279,276 
Aldehyde dehydrogenase 396,212 397,484 
Dehydrogenase 397,758 398,668 
Thymidylate kinase 439,535 439,798 
Transcription-repair coupling factor 577,987 580,330 
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Table 3-6. New genes proposed to be involved in ET-743 biosynthesis in Ca. E. 
frumentensis.  
Gene 
Product 
Function Putative Role Coordinates (bp) 
Start End 
EtuP3 Pyruvate dehydrogenase-E3 
Component 
Assists EtuP1, EtuP2, and EtuF9 
in supplying the glycolicacyl-S-
ACP extender unit (5) for NRPS 
266,073 267,440 
EtuO2 Flavodoxin reductase (ferredoxin 
NADPH reductase), phenol 
hydroxylase  
Possible hydroxylation (7) or 
methylenedioxy bridge (11) 
formation 
280,797 281,537 
EtuM3 O-Methyltransferase  EtuA2 substrate formation (6) or 
later methylation 
285,669 286,331 
EtuY Carbonic 
anhydrase/acetyltransferase  
Acetylation to make 7 286,333 286,884 
EtuO3 Flavoprotein  Possible hydroxylation (7), 
methylenedioxy bridge (11), or 
involvement in CoA biosynthesis 
286,966 287,511 
EtuO4 Flavoprotein  Possible hydroxylation (7), 
methylenedioxy bridge (11), or 
involvement in CoA biosynthesis 
287,508 288,164 
EtuM4 N-Methyltransferase  N-methylation to make 9 360,210 361,064 
EtuF4 birA, biotin-[acetyl-CoA-
carboxylase] ligase  region 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
370,417 371,433 
EtuF5 3-hydroxyacyl-[acyl-carrier-
protein] dehydratase 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
374,717 375,166 
EtuF6 phosphate:acyl-[acyl carrier 
protein]  acyltransferase 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
435,106 436,137 
EtuF7 malonyl CoA-acyl carrier protein 
transacylase 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
436,188 437,078 
EtuF8 3-oxoacyl-[acyl-carrier-protein] 
reductase 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
437,153 437,905 
EtuF9 Acyl Carrier Protein Possible loading of glycolic acid 
for the NRPS enzyme EtuA1  
437,952 438,188 
EtuF10 beta-ketoacyl-acyl-carrier-protein 
synthase II 
Fatty acid biosynthesis and/or 
substrate formation for the NRPS 
enzyme EtuA3 
438,293 439,534 
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3.5 Materials and Methods 
Sample Collection and Isolation of Metagenomic DNA.  Two tunicate colonies were 
collected off the coast of the Florida Keys.  Animals were immediately frozen on dry ice 
after collection and stored at -80°C until processing.  Metagenomic DNA was isolated 
from single zooids plucked from each colony (Figure 3-5) following the protocol 
outlined for mouse tails in the Wizard Genomic DNA Purification Kit (Promega).  
Metagenomic DNA samples were shipped on dry ice to the Joint Genome Institute (JGI) 
for immediate shotgun sequencing with Illumina HiSeq technology. 
 
Genome Sequencing, Assembly, Binning and Annotation. The four metagenomic 
samples were sequenced and assembled by JGI. Gene calling and annotation of the 
assembled metagenome was then completed through JGI IMG/M (149).  Individual 
contigs from each assembly were assigned to taxonomic groups through binning with 
tetranucleotide frequency with ESOM as described previously (95). Since the 
metagenomes had an excess of sequences belonging to the eukaryotic host tunicate, 
iterative rounds of ESOM were required to hone in on microbial communities present in 
the sample.   
 
Genes from the previously identified ET-743 biosynthetic gene cluster (91) and the 16S 
gene for E. frumentensis (89-91) were used as BLAST queries to identify the bin 
containing the ET-743 producer in each of the four metagenomic samples. The four 
resulting bins were manually evaluated for completeness through the analysis of the 
distribution of conserved phylogenetic markers (150).  Contigs from the four bins were 
assembled into a consensus genome with Geneious (v. 7.1.3).   
 
Filing Genomic Gaps 
We designed primers upstream of any suspected genomic gaps and carried out PCR using 
KOD XtremeTM Hot Start DNA Polymerase (Novagen).  Reactions contained 0.02 U/µL 
polymerase, 1X of the supplied buffer, 0.3 µM custom primers, 0.4 mM each dNTP, and 
100 ng of metagenomic DNA.  Reactions consisted of a hot start (94 °C, 2 min), followed 
by 35 cycles of denaturing (98 °C, 10 sec), annealing (variable temperatures for 30 sec), 
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and extension (68 °C for variable times).  Since we were unsure about the size of 
genomic gaps, we began with a longer extension time of 5 minutes.  If we saw a DNA 
band after running reactions on a 1% agarose gel, we repeated PCR and tailored the 
extension time to the size of the band (1 min/kbp) to limit any nonspecific amplification.  
Amplified DNA was then isolated from agarose gels using the standard protocol from the 
Wizard® SV Gel and PCR Clean-Up Kit (Promega).   
 
Samples were submitted for Sanger sequencing with the primers used in the PCR 
reactions. Primer walking along the DNA strand then provided the missing sequence 
within both gaps.  The complete consensus genome was submitted to JGI IMG (151) for 
gene calling and annotation.  The final genome was reassessed for the completeness and 
accuracy through analysis of the distribution of conserved phylogenetic markers (150).  
 
Genome Analysis  
The common genes included in Figure 3-7 were compiled from other studies examining 
genome reduction in endosymbionts and intracellular pathogens (98, 152).  Analysis of 
primary metabolic pathways was completed using the KEGG and MetaCyc annotations 
provided through JGI/IMG.  To confirm the absence of any missing genes, protein 
sequences from a model organism (typically from E. coli E12) were used as queries in a 
BLASTP search against the Ca. E. frumentensis annotated genome.   
 
To detect pseudogenes, all intergenic regions larger than 100 bp were used as BLASTX 
queries against the entire NR database using default settings.  Any hits with e-values 
lower than 1x10-3 against nonhypothetical proteins were considered pseudogenes.  
 
Visualization of the complete genome (Figure 3-2) was constructed using Circos (153).  
Data for circles displaying Pfam categories for protein-coding genes, genes on the plus 
strands, and genes on the minus strands was provided directly through JGI IMG 
annotations and analysis.   
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Phylogenetic Analysis 
The gene sequences for conserved phylogenetic markers (16S rRNA, rpoB, and recA) 
were used as BLASTN queries against the NT database.  Trees were constructed with 
Geneious (v. 7.1.3) after ClustalW multiple alignments with an IUB cost matrix (default 
settings).  Neighbor-joining trees were constructed with the Jukes-Cantor genetic distance 
model (default settings).  Top hits for cultured or well-studied uncultured microorganisms 
were included in the phylogenetic tree for 16S rRNA gene sequences.  All unique hits for 
rpoB and recA were used in respective genetic trees.  
 
To further explore taxonomic uniqueness (Figure 3-9), the complete or draft genomes of 
the top hits from phylogenetic analysis were used in a two-way BLAST against Ca. E. 
frumentensis to acquire average amino acid identity (AAI) as previously described (105).  
Thresholds for unique taxonomic rankings were based on 16S rRNA gene sequence 
identity as previously described (106).  
3.6 Notes and Author Contributions  
A portion of this chapter was submitted to the Proceedings of the National Academy of 
Sciences of the United States of America during the preparation of this dissertation: 
 
*Schofield MM, *Jain S, Porat D, Dick GJ, Sherman DH. “Identification and analysis of 
the bacterial endosymbiont specialized for production of the chemotherapeutic natural 
product ET-743.” Submitted to Proc Natl Acad Sci U S A. Asterisks denote authors that 
contributed equally to this work.   
 
Author contributions are as follows: Michael M. Schofield, Sunit Jain, Gregory J. Dick, 
and David H. Sherman contributed to the experimental design.  Michael M. Schofield 
collected samples and isolated metagenomic DNA with assistance from Daphne Porat.  
Sunit Jain carried out tetra-ESOM, identified the ET-743 producing bin, and determined 
coverage. Michael M. Schofield filled genomic gaps and carried out secondary 
assemblies to acquire a consensus genome.  Sunit Jain carried out analysis to determine 
taxonomic uniqueness. Michael M. Schofield carried out analysis of the genome, its 
primary metabolism, and its secondary metabolism.  Michael M. Schofield, Sunit Jain, 
Gregory J. Dick, and David H. Sherman evaluated the data.  
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Chapter 4 
Accessing natural products from uncultured bacteria:  
Initial Biochemical Investigations of ET-743 Biosynthetic Enzymes 
4.1 Introduction  
Accessing natural products from uncultured microorganisms can present a unique 
challenge.  The inability to grow these organisms in the laboratory using standard 
techniques limits large-scale production for pharmaceutical applications.  Many of these 
compounds are also isolated in extremely low yields from their natural environment.  
Therefore, harvesting plants, animals, sediments, or any environmental material the 
microorganisms inhabit is often economically and environmentally unsustainable.  To 
combat these problems, the natural products of many uncultivated microorganisms are 
currently accessed synthetically.   
 
However, many of these bioactive compounds have extremely complex structures, 
making total or even semi-synthesis a lengthy and costly process.  The synthetic 
generation of extensive libraries to identify more potent and selective natural product 
analogues also presents a substantial challenge (154).  It is critical that we continue to 
find new ways to access these medicines. Understanding the biology of the uncultured 
microorganisms responsible for the production of natural products provides a critical 
foundation for this goal. 
 
The complete genome presented in chapter 3 elucidated the primary and secondary 
metabolism of Ca. E. frumentensis, the uncultured bacteria responsible for production of 
ET-743. Using this valuable information, we can begin to concurrently pursue different 
routes to access the chemotherapeutic drug ET-743 (Figure 4-1).     
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Figure 4-1. An outline of currently pursued routes to access the chemotherapeutic natural 
product ET-743  
A.) Reconstitute the compound’s core using purified NRPS enzymes in vitro (described in this 
chapter).  B.) Utilize information gleaned from the genome of Ca. E. frumentensis to cultivate the 
microorganism in a laboratory setting (described in chapter 5).  C.) Directly produce the natural 
product and new analogous in a cultured host organism through genetic engineering (described in 
chapter 5).   
 
One particularly intriguing course to access natural products from uncultured 
microorganisms is through their in vitro reconstitution using key biosynthetic enzymes 
(Figure 4-1A). Enzymes called nonribosomal peptide synthetases (NRPS) are 
responsible for biosynthesizing the core structures of many natural products, including 
ET-743.  Members of this fascinating class of enzymes form a complex assembly line to 
biosynthesize natural products that are then tailored with additional chemical groups by 
accessory enzymes.  NRPS enzymes are organized into distinct modules that are each 
responsible for incorporating one amino acid or substrate into the core of the natural 
product.  The simplest NRPS module contains 3 domains, including a condensation (C) 
domain, adenylation (A) domain, and a thiolation (T or PCP) domain.  The A domain 
activates the substrate and loads it onto the T domain.  The C domain then catalyzes the 
formation of a new peptide bond between the loaded substrate and growing natural 
product core.  NRPS modules can additionally possess a wide variety of other domains 
that provide further structural diversity to the natural product.  
 
As described in chapter 3, the core of the chemotherapeutic natural product ET-743 is 
likely biosynthesized by three NRPS enzymes encoded in the genome of Ca. E. 
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frumentensis (Figure 4-2, Figure 4-3A).  These enzymes represent ideal first targets to 
begin work toward in vitro reconstitution of ET-743 and new analogues.  This is because 
NRPS enzyme complexes are prone to manipulation from several different routes.  For 
example, they can frequently display substantial substrate flexibility.  This allows us to 
feed the enzymes unnatural substrates that they can incorporate into the growing natural 
product core.  Similar natural products also have fairly conserved NRPS modules. For 
example, the NRPS modules found in ET-743 are similar to those found in other 
tetrahydroisoquinoline natural products (Figure 4-2).  This allows us to mix and match 
enzymes from different systems to create unique natural product hybrids. The natural 
product cores produced by NRPS enzymes can also be combined with semi-synthetic 
methods to create unique compounds through chemoenzymatic synthesis (154, 155).  
 
 
Figure 4-2. Four tetrahydroisoquinoline natural products and the conserved NRPS modules 
responsible for the biosynthesis of their cores. 
A.) The structures of the four best-studied tetrahydroisoquinoline natural products, their names, 
and the microorganism responsible for their production.  The NRPS enzymes EtuA1-3 are 
responsible for construction of the core (shown in red) in ET-743.  B.) The NRPS modules 
responsible for production of tetrahydroisoquinoline cores are conserved between 
microorganisms.  AL-acyl ligase; T-thiolation; C-condensation; A-adenylation; RE-reductase. 
 
The complete genome of Ca. E. frumentensis and studies of other tetrahydroisoquinoline 
natural products (121-123) helped us understand how these three NRPS enzymes likely 
work together to biosynthesize ET-743 (Figure 4-3).  We predict that the NRPS 
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dimodule EtuA3 (AL-T-C-A-T) initiates production of the ET-743 core by loading an 
acyl chain onto the adjacent T domain. The second module of the enzyme then activates 
and loads a cysteine onto the growing chain.  The growing natural product core is then 
passed to the NRPS EtuA1which incorporates a glycolic acid, possibly with the help of 
the transketolases EtuP1-3 and a downstream acyl carrier protein (ACP).  The reductase 
(RE) domain of EtuA2 is then thought to terminate the reaction and release the 
nonribosomal peptide.  The remaining domains of EtuA2 then combine the product from 
EtuA3 and EtuA1 with a tyrosine derivative (3-hydroxy-4-O-methyl-5-methyl-tyrosine, 
3H-4O-Me-5Me-Tyr) in multiple rounds of a cyclizing Pictet-Spengler reaction to create 
the final ET-743 natural product core (Figure 4-3).  
 
In this investigation, we sought to take the first steps toward in vitro reconstitution and 
manipulation of the tetrahydroisoquinoline core of ET-743.  Codon optimization enabled 
us to clone the NRPS genes and express the enzymes responsible for production of the 
molecule’s core.  We then selected the most promising of these enzymes (EtuA1) for 
analysis.  Our biochemical study of the enzyme provided the first experimental evidence 
of its role in ET-743 biosynthesis. Analysis of its substrate flexibility also highlighted the 
potential to use the enzyme to generate new ET-743 analogues in future studies.       
 
This investigation provides a firm foundation for continuing efforts to reconstitute the 
ET-743 biosynthetic core in vitro with these enzymes.  This route could prove an 
important method to access ET-743 and new analogues.  The beginning stages of 
accessing the natural product though other routes, including cultivation of the producing 
organism (Figure 4-1B) and engineering of genomes from Streptomyces species (Figure 
4-1C) are described in chapter 5.   
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Figure 4-3. Biosynthesis of the ET-743 biosynthetic core.   
A.) Putative genes involved in biosynthesis of the ET-743 biosynthetic core.  B.) The 
corresponding gene products and their predicted roles in ET-743 biosynthesis.  NRPS enzymes 
are shown in red.  The pyruvate dehydrogenase enzymes EtuP1-P3 (purple) possibly acquire 
glycolic acid from a primary metabolic pathway and deliver it to EtuA1 using the ACP EtuF9 
(green).  Contributions by the NRPS enzymes are shown in red in the final structure for ET-743.     
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4.2 Results 
4.2.1 Codon optimization permits expression and purification of enzymes involved 
in ET-743 biosynthesis.  
Attempts to heterologously express ET-743 enzymes in E. coli and many other host 
organisms were largely unsuccessful for many years (91) despite trying multiple 
methodologies and exploring various host organisms.  We never observed protein 
expression, although genes always amplified well from tunicate metagenomic DNA and 
were typically easy to clone into expression vectors. 
 
Previous metagenomic analysis (91) and our work in chapter 3 suggested the likely cause 
of this is the extremely low %G+C content of Ca. E. frumentensis DNA.  The genome 
possesses an overall 23.3% G+C content, with 24.2% found in the coding regions and 
12.7% found in the noncoding regions.  Every amino acid is capable of being encoded by 
more than one codon, and different organisms can have vastly differing codon 
preferences.  One of the driving forces that determines these codon preferences is the 
G+C makeup of the genome (156).   
 
We examined the codons used by the three NRPS genes and compared them to codon 
preferences of varying host organisms, including E. coli, yeast species, and varying 
species of actinomycetes.  The results illustrated drastic codon differences and suggested 
that codon optimization could finally enable expression of ET-743 biosynthetic enzymes 
in heterologous hosts (Figure 4-4).    
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Figure 4-4. Ca. E. frumentensis utilizes different codons from many commonly used 
heterologous hosts. 
The relative adaptiveness of codons for the first 50 amino acids in EtuA1 A.) before codon 
optimization of the gene and B.) after codon optimization of the gene for expression in E. coli.  
Red bars indicate poor codon agreement while black bars indicate good agreement.   
 
We therefore purchased codon optimized fragments of the three ET-743 NRPS genes and 
utilized Gibson assembly to piece the fragments together and clone them into various E. 
coli protein expression vectors (Table 4-1 in Supplemental Information [SI]).  This 
resulted in expression of each NRPS enzyme for the first time (Figure 4-8 in SI).   
 
Although proteins expressed well, we next encountered solubility issues during the 
purification process.  Utilizing an expression vector possessing the maltose binding 
protein (MBP) solubility tag, adding the chemical chaperone trimethylamine N-oxide 
(TMAO), and utilizing other solubilizing reagents partially corrected these solubility 
problems.  However, purification of the enzymes by both nickel and amylose affinity 
chromatography was still suboptimal, (Figure 4-9 in SI) and yields were too low to 
attempt additional purification steps, such as size-exclusion chromatography.   
 
Previously published (157) and unpublished work in our laboratory demonstrated that 
clean protein preps are not always necessary to conduct biochemical analysis or complete 
chemoenzymatic studies.  We can still conduct simple biochemical analyses and generate 
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natural products using suboptimal protein preparations or even whole cell extracts.  In 
fact, these methods can actually facilitate easier production of natural products on a larger 
scale.   
 
We therefore decided to select the best behaving of the three ET-743 NRPS enzymes and 
continue our analysis using its suboptimal protein preparations.  Of the three enzymes, 
EtuA1 expressed the best, was the most soluble, and was the easiest to purify (Figure 4-
9).  Our biochemical and substrate flexibility analysis with this enzyme represent a model 
that can be used for future work with EtuA2 and EtuA3.  
 
Figure 4-5. The role of EtuA1 in the biosynthesis of ET-743 
A.) Putative genes involved in biosynthesis of the ET-743 biosynthetic core, including EtuA1.  
B.) The corresponding gene products and their predicted roles in ET-743 biosynthesis, with a 
focus on the role of EtuA1.  We predict the enzyme incorporates glycolic acid into the growing 
natural product.  However, the role of EtuP1-3 and EtuF9 is unknown.   
 
4.2.2 Biochemical assessment of EtuA1, an NRPS that selectively activates glycolic 
acid. 
Based on analysis of the biosynthetic gene cluster presented in chapter 3, we predicted 
that EtuA1 is likely responsible for incorporating glycolic acid into the core scaffold of 
ET-743.  However, it was unclear what role the transketolases EtuP1-3 and the ACP 
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EtuF9 played in helping EtuA1 incorporate glycolic acid (Figure 4-5).  Previous 
evidence in another tetrahydroisoquinoline system suggested that these enzymes may be 
necessary for successful NRPS incorporation of glycoaldehyde units into natural products 
(126).  Similar enzymes in the biosynthesis of quinocarcin, naphthyridinomycin, and SF-
1739 acquire the glycoaldehyde unit from a primary metabolic pathway, load it onto a 
separate ACP, and incorporate it directly onto the NRPS module (124, 126).  If this was 
the case with EtuA1, we would expect the A domain would be incapable of activating 
glycolic acid on its own.      
 
To test the ability of the A domain of EtuA1 to activate and load glycolic acid, we again 
utilized the malachite green assay outlined in chapter 2.  Briefly, A domains recognize 
and activate a substrate using the coenzyme adenosine triphosphate (ATP).  During the 
enzymatic reaction, they release pyrophosphate (PPi).  The malachite green assay utilizes 
inorganic pyrophosphatase to cleave PPi  which is then able to complex with a quenching 
solution to produce a colorimetric change.  This permits us to visualize whether NRPS 
and related enzymes are capable of activating substrates.  After significant optimization, 
the malachite green assay was found to be robust for use with EtuA1 with a Z-factor of 
0.574 (Figure 4-10 in SI).’ 
 
 
 
 
 
 
 
100 
 
 
Figure 4-6. EtuA1 preferentially activates glycolic acid over other predicted substrates  
The optimized malachite green assay was utilized with EtuA1 using glycolic acid, a 
tyrosine derivative (predicted substrate for EtuA2), and cysteine (predicted substrate for 
EtuA3).  The enzyme preferentially activated glycolic acid over other substrates, 
indicated by the significantly higher absorbance readings.  
 
 
The optimized assay was used to test the ability of the A domain of EtuA1 to accept 
glycolic acid over 3H-4O-Me-5M3-Tyr and cysteine, the predicted substrates for EtuA2 
and EtuA3 respectively.  The enzyme was shown to activate glycolic acid, but not the 
tyrosine derivative or cysteine (Figure 4-6).  This provided the first experimental 
evidence that EtuA1 is indeed involved in incorporating glycolic acid into the final 
structure of ET-743.  It also suggests that the role of EtuA1 may be unique from those of 
similar enzymes found in other tetrahydroisoquinoline biosynthetic pathways.  The NRPS 
may not require direct interaction with the transketolase enzymes and an ACP to activate 
and load glycolic acid units.  
4.2.3 EtuA1 exhibits some promiscuity in substrate activation  
We were next interested in examining the substrate flexibility of EtuA1.  Probing the 
ability of the A domain to activate unnatural substrates could help us predict the 
feasibility of using in vitro enzymatic reactions to create new ET-743 natural product 
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analogues.  We therefore selected a variety of substrates (Figure 4-7A) to test against the 
enzyme.  
 
Figure 4-7. Examination of the substrate flexibility of EtuA1  
A.) The structures of the various substrates tested against EtuA1. The natural substrate, glycolic 
acid, is highlighted in yellow. B.) The malachite green assay was used to assess the ability of the 
EtuA1 A domain to activate substrates.  Data are normalized to the preferred substrate, glycolic 
acid.    
 
EtuA1 preferentially activated glycolic acid over other tested substrates (Figure 4-7B).  
However, the A domain did seem capable of activating a few unnatural substrates, 
particularly 3-mercaptopropionic acid and isobutyric acid.  This demonstrates that the 
enzyme is capable of some promiscuity and could potentially incorporate intriguing 
chemical groups into ET-743 to generate new analogues.        
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4.3 Conclusions 
In vitro reconstitution of key biosynthetic enzymes can be an effective method to access 
natural products.  Manipulation of individual enzymes with unnatural substrates also 
presents the potential to generate novel analogues with better potency or selectivity for 
molecular targets.  In this investigation, we have taken the first steps toward in vitro 
reconstitution of the ET-743 core by examining one of the key enzymes involved in its 
biosynthesis.   
 
We presented biochemical evidence that EtuA1 is directly capable of activating glycolic 
acid, unlike its relatives in the quinocarcin, naphthyridinomycin, and SF-1739 
tetrahydroisoquinoline systems (124, 126).  Although EtuA1 is obviously capable of 
activating a glycolic acid substrate, it is still unclear whether or not the enzyme can 
successfully load the substrate and condense it onto the growing peptide chain.  We need 
to complete further studies with EtuA1 and the remaining NRPS enzymes to answer these 
questions.    
 
Studies of other NRPS systems have illustrated that it is possible for some enzymes to 
directly load α-hydroxyacids onto nonribosomal peptides without assistance from 
transketolases (158).  Alternatively, other systems load α-ketoacids that are then directly 
reduced to a α-hydroxyacid by a ketoreductase while tethered to the assembly line (159, 
160).  What method EtuA1 uses to incorporate glycolic acid remains unclear. However, 
the close proximity of the transketolase genes to the NRPS genes (Figure 4-5) suggests 
they likely play some important role, if only acquiring glycolic acid substrate from a 
primary metabolic pathway for direct use by the NRPS. 
 
The substrate flexibility of EtuA1 also validates that in vitro enzymatic studies could 
provide an effective route for the generation of new ET-743 analogues.  The ability of the 
enzyme’s A domain to activate unnatural substrates suggests that the enzyme could be 
capable of incorporating unusual units into the final structure of ET-743. The substrates 
tested against EtuA1 in this investigation were by no means extensive, and it would be 
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interesting to explore what other types of chemical groups the enzyme is capable of 
recognizing.   
 
In summary, this investigation provides a firm foundation for further efforts to 
reconstitute the ET-743 core scaffold in vitro using purified NRPS enzymes.  The 
methodologies developed here with EtuA1 provide an effective roadmap for future 
efforts with EtuA2 and EtuA3.  With further work, these techniques could provide direct 
access to ET-743 and new analogues, bypassing the costly and lengthy synthetic route 
currently used by pharmaceutical companies.        
 
4.4 Supplemental Information  
 
Gene Product and 
Predicted Function 
Vector  Expression Best Purification 
Conditions 
Solubility  
EtuA1, NRPS  
(Glycolic Acid) 
pET30 Yes, Codon Optimized Only TMAO, AI cells Poor 
pMCSG7 Yes, Codon Optimized Only TMAO, AI cells Poor 
pTrc9 Yes, Codon Optimized Only TMAO, Nickel over 
amylose affinity  
Decent 
EtuA2, NRPS 
(Tyr derivative) 
pMCSG7 Yes, Codon Optimized Only TMAO, AI cells None 
pTrc9 Yes, Codon Optimized Only TMAO, Nickel over 
amylose affinity 
Poor 
EtuA3, NRPS 
(Cysteine)  
pMCSG7 Yes, Codon Optimized Only TMAO, AI cells None 
pTrc9 Yes, Codon Optimized Only TMAO, Nickel over 
amylose affinity 
Poor 
Table 4-1. Cloned constructs for expression of EtuA1-3  
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Figure 4-8. Expression of various ET-743 biosynthetic enzymes   
The vector pTrc9 with an MBP fusion tag produced the best expression of EtuA1-3 in E. coli 
Bap1 cells.  This gel is an expression test and depicts whole cell extracts.  Overexpression of each 
protein is depicted by the yellow arrows in cultures that have been induced (I) and not induced 
(NI) with isopropyl β-D-1-thiogalactopyranoside (IPTG).  The T7 promoter in pTrc9 is a little 
leaky, causing some expression in non-induced cultures.  
 
 
Figure 4-9. Suboptimal purification of EtuA1-3 NRPS modules    
EtuA1-3 displayed significant solubility problems during the protein purification process.  
Although enzymes were far from pure, further purification techniques like size exclusion 
chromatography would have a negative impact on the yield of target proteins.  We selected EtuA1 
(A) over EtuA2 (B) and EtuA3 (C) because it provided the best yield and the enzyme was the 
most soluble to work with.  Left facing arrows depict target enzymes, confirmed with western 
blots against the 6x poly-histidine tag (data not shown). 
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Figure 4-10. Optimization of the malachite green assay for biochemical analysis of EtuA1  
A.) We tested various concentrations of enzyme during assay optimization.  5 µM produced the 
best Z factor and was used for final assay conditions.  B.) We also tested varying incubation times 
and the optimal time after quenching to read the assays.  We selected 20 minutes after quenching 
for reading, based on its excellent Z factor (0.574) and consistently lower standard error.   
 
4.5 Materials and Methods 
Cloning and protein purification.  
The etuA1, etuA2, and etuA3 genes were codon optimized for expression in E. coli using 
the Graphical Codon Usage Analyzer (GCUA) and ordered in fragments from Gene 
Strings (Invitrogen).  The codon-optimized fragments were then assembled into various 
vectors with LIC overhangs using Gibson Assembly Master Mix (NEB).   
 
To obtain purified protein from constructs, we attempted various expression and 
purification conditions with different vectors, cell lines, buffers, and reagents.  
Conditions that achieved the best results (Figure 4-9 in SI) included expression in the 
pTrc9 with an MBP fusion tag in Bap1 cells.  Cells were grown in Terrific Broth (TB) at 
37 °C with 200 mM TMAO until they reached a high OD (~2.0, ideal for toxic protein 
products).  Cultures were then cooled to 18 °C, induced with 1 mM IPTG, and left to 
express for 6 hours.    
 
Harvested cell pellets were lysed by sonication in a buffer containing 200 mM TMAO, 
40 mM imidazole, 20 mM HEPES, 300 mM NaCl, 1 mM tris (2-carboxylethyl) 
phosphine (TCEP), 20% glycerol, a cocktail of protease inhibitors (EDTA-free Complete, 
Roche), 400 mg CellLytic Express (Sigma), and ~5 mg of lysing enzymes from 
Trichoderma harzianum (Sigma L1412).  The cell-free extract was collected by 
ultracentrifugation at 45,000 x g for 45 minutes.  The supernatant was subjected to flash 
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Ni2+ affinity chromatography after batch binding with nickel resin for 2 hours.  Resin was 
rinsed with 100 mL of the lysis buffer before elution with lysis buffer including 300 mM 
imidazole.  Protein preps were immediately frozen in the high imidazole buffer and 
stored at -80°C until analysis since any kind of buffer exchange system would result in 
protein yield loss to some degree.   
 
Malachite green assays. Malachite green assays were based off of previous work 
(described in chapter 2).  However, we optimized conditions to maximize the efficiency 
of the assay with EtuA1.  Assays were performed in a 384-well plate format with a final 
volume of 40 µL. Enzymatic activity was found to be most uniform across clear 
polystyrene microplates produced by Greiner Bio-One (781185).  Standard final 
conditions were 20 mM HEPES, pH 7.5, 5 mM MgCl2, 2.25 mM ATP, 15 mM of various 
substrates, 0.2667 U/mL inorganic pyrophosphatase (IPP), and 5 µM EtuA1.  Reaction 
mixtures were split into two solutions: a substrate solution and an enzyme solution to 
initiate reactions.  First, 30 µL of a substrate mix containing HEPES, MgCl2, ATP, 
substrate, and IPP was dispensed into the 384-well plate.  To initiate the reactions, 10 µL 
of an enzyme solution containing HEPES and purified EtuA1 was added to the reactions.  
Reactions were incubated for 1.5 hours at room temperature before quenching with a 
malachite green solution as described in chapter 2.  Quenched reactions were incubated 
for 20 minutes before reading at Abs600.  
 
4.6 Notes and Author Contributions  
The work described in this chapter is ongoing.  Michael M. Schofield and David H. 
Sherman contributed to experimental design.  Michael M. Schofield conducted all 
cloning and experiments with some assistance from undergraduate students, including 
Daphne Porat.  Chemist and Sherman laboratory member Jennifer Schmidt provided 
invaluable advice on initial substrates to test against EtuA1.     
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Chapter 5 
Discussion and Future Work 
5.1 Overview 
Microbial natural products are a critical source for novel medicines in the ongoing war 
against drug resistant microorganisms, viruses, fungi, and cancers.  To maximize the 
discovery of new chemical scaffolds, we need to concurrently explore the natural 
products of both cultured and currently uncultured microorganisms.  This dissertation has 
outlined various methodologies that can facilitate access to medicines from both of these 
microbial sources (Figure 5-1).   
 
In chapter 2, I described our work to find novel natural products from cultured bacteria.  
We first identified an ideal drug target—an enzyme that helps construct a molecule 
involved in microbial iron acquisition. We then used this drug target to screen an 
extensive library composed of extracts from thousands of cultured microorganisms for 
potential new natural product medicines.  This led to the identification of a novel 
antibiotic scaffold that we demonstrated could be used as a broad-spectrum antibiotic.  
This targeted high throughput screening technique could be a powerful method to 
continue to identify new drugs to fight off resistant infections.  
 
In chapters 3 and 4, I described our work to find new natural product medicines from 
uncultured bacteria.  For both of these chapters, we selected the chemotherapeutic drug 
ET-743 as a model system.  Researchers have long suspected that an uncultured microbe 
was responsible for the drug’s production.  Decades’ worth of work into ET-743 and 
other tetrahydroisoquinoline natural products provided a perfect foundation and 
knowledgebase for our work. 
 
In chapter 3, we first sought to identify and understand the uncultured microorganism 
responsible for ET-743 production.  We used metagenomic methodologies to uncover the 
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complete genome of Ca. E. frumentensis.  We provided strong evidence that the microbe 
is an endosymbiont inhabiting the cells of its mangrove tunicate host.  We also conducted 
an in-depth analysis of its primary and secondary metabolism, providing a thorough look 
at the endosymbiont’s lifestyle and its biosynthetic pathway.  This understanding 
provided an essential knowledgebase that we could then use to begin to develop new 
routes to access the elusive natural product.  
 
In chapter 4, we began to explore one of these routes.  We heterologously expressed key 
ET-743 biosynthetic enzymes for the first time.  We then biochemically analyzed one of 
these key enzymes (EtuA1) and provided evidence for its predicted role in ET-743 
biosynthesis.  We also provide data that suggests that its role may be different than 
similar enzymes in other tetrahydroisoquinoline systems.  In addition, we explored the 
substrate flexibility of the enzyme.  Our experiments in this chapter illustrate that EtuA1 
and the rest of the NRPS assembly line could be used to reconstitute the ET-743 core in 
vitro and possibly to generate new analogues. 
 
In this chapter, I will explore our ongoing and future work for the baulamycin and ET-
743 projects.   
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Figure 5-1. A review of my dissertation 
Chapter 2 described efforts with a targeted high throughput screen from an extract library to 
identify novel natural products.  Chapters 3 and 4 outlined techniques to access the products of 
uncultured microorganisms.  In chapter 3, we utilized metagenomic methods to understand an 
uncultured microorganism.  In chapter 4, we used this new information to begin work that could 
one day enable us to access its natural product.  Here in chapter 5, we describe future directions 
and ongoing work for both of these projects.   
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5.2 Ongoing and future work for cultured microorganisms  
5.2.1 Identification and manipulation of the baulamycin gene cluster to increase 
antibiotic production and make more potent analogues  
 
The strain that produces the baulamycin antibiotics described in chapter 2 (Figure 5-2A) 
is cultured in the laboratory using standard techniques. The genes responsible for natural 
product biosynthesis are usually tightly clustered within genomes.  The ability to 
cultivate the baulamycin-producing strain therefore provides direct access to the 
antibiotics and the ability to easily create more potent and selective analogues. 
 
 
 
Figure 5-2. Identification of the PKS gene cluster responsible for baulamycin biosynthesis. 
A.) The structure of the baulamycin antibiotics described in chapter 2.  The highlighted region 
depicts the key difference between BmcA and BmcB and the likely cause for observed 
differences in their efficacy. B.) The polyketide synthase (PKS) gene cluster responsible for the 
biosynthesis of the baulamycin antibiotics.  Gene names relate to the proposed function for each 
protein: M, methyltransferase; O, monoxygenase; H, hypothetical proteins; S, enzymes 
responsible for biosynthesis of the starter unit; M, methyltransferase; P, polyketide synthase; R, 
regulatory proteins; D, enzymes responsible for biosynthesis of the first extender unit.     
 
To identify the gene cluster responsible for baulamycin biosynthesis, we mined Illumina 
sequencing data of the producing microorganism, Streptomyces tempisquensis.  The 
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structure of the baulamycins (Figure 5-2A) suggested that a type 1 polyketide synthase 
(PKS) enzyme was likely involved in the biosynthesis of the compounds.  Mining 
sequencing data for type 1 PKS genes in conjunction with Drs. Fengan Yu and 
Ashootosh Tripathi from our laboratory led to the identification of the baulamycin 
biosynthetic gene cluster (Figure 5-2B). 
 
Since my departure from this project, Drs. Ashootosh Tripathi and Sung Ryeol Park from 
our laboratory have begun pursuing a number of different methods with this gene cluster 
to understand and manipulate the biosynthesis of the baulamycin antibiotics (Figure 5-3).  
 
 
Figure 5-3. Long-term goals of the baulamycin project. 
A.) Increase production of the baulamycins from the producing strain, S. tempisquensis. B.) 
Elucidate the biosynthetic pathway for baulamycin production and biochemically confirm key 
steps. C.) Generate new baulamycin analogues through gene cluster manipulation in the native 
strain and/or in vitro studies of key enzymes.  
 
One of the major hurdles in chapter 2 was the extremely low yields of baulamycin 
production by S. tempisquensis.  This limited our ability to explore the mechanism of 
action of these compounds and complete detailed studies of their efficacy against 
pathogenic microorganisms.  Ongoing work by Drs. Tripathi and Park to increase the 
yield of the baulamycin compounds (Figure 5-3A) includes varying growth conditions of 
the producing strain and utilizing previously described ribosomal engineering methods 
(161, 162) to increase production of biosynthetic enzymes.  This will hopefully increase 
our ability to isolate large amounts of the drug and eventually more potent analogues, 
facilitating pre-clinical studies.   
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Dr. Tripathi has also proposed a pathway for baulamycin production and begun in vitro 
analysis to biochemically confirm key steps of the antibiotics’ biosynthesis (Figure 5-
3B).  Heterologous expression of key genes in E. coli has already confirmed one key 
biosynthetic step in the pathway.  Confirmation of remaining steps with other cloned 
constructs is still in progress.  Ongoing and future in vitro work with remaining enzymes 
and knockouts of corresponding genes in S. tempisquensis will help elucidate baulamycin 
biosynthesis (Figure 5-3B) and provide insight into the pathway’s potential flexibility to 
incorporate unnatural substrates and generate new analogues (Figure 5-3C).  
 
Generating more potent analogues is a particularly intriguing future direction for the 
baulamycin project (Figure 5-3C).  The drastically increased efficacy of BmcA (4.9 µM 
SbnE/180 µM AsbA) over BmcB (19 µM SbnE/200 µM AsbA) shown in chapter 2 is 
likely due to the extended carbon chain present in the compound (Figure 5-2A).  This 
suggests that tailoring the compound could have a drastic impact on its potency against 
pathogenic microorganisms.  The incorporation of a longer carbon chain or additional 
methyl branching in particular could result in a more potent antibiotic.  It would also be 
interesting to explore whether or not the compound could be cyclized and what effect this 
would have on its overall potency and selectivity for NIS synthetases.  
5.2.2 Identifying additional natural product inhibitors of siderophore biosynthesis  
 
In chapter 2, we pursued the best hit from our high throughput screen against an 
expansive natural product extract library. The cultured microorganism corresponding to 
this hit (S. tempisquensis) led to the discovery a new class of broad-spectrum antibiotics.  
There could be additional unique antibiotics hiding within other hits from the high 
throughput screen. To explore this possibility, we went back to examine the original 
screening results (Table 5-1). 
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Strain AsbA 
Growth 
Variants 
AsbA 
Top Hit (%) 
AsbA 
Total 
Hits 
SbnE 
Growth 
Variants 
SbnE 
Top Hit (%) 
SbnE 
Total 
Hits 
34946 N9I 88.83 5 N12N, N23I, 
N9I, N9N 
97.43 12 
05545 I, N 72.77 6 I, N 86.53 6 
44478 N5I, N5N 88.67 4 N5I, N5N 96.7 5 
44341 A3N 83.47 5 A3N 98.5 4 
58069 I 76.93 1 I 97.13 4 
34362 A2N 90.2 2 A2N 98.7 2 
5732 A2I 79.17 2 A2I 95.1 2 
58195 I 76.03 2 I 96.2 2 
5732 A2I 79.17 2 A2I 98.1 2 
Table 5-1. Top hits active against both AsbA and SbnE in the high throughput screen 
against the natural product extract library.  
The top hits from the original high throughput screen against both enzymes. Extracts in the 
library are derived from strain growth in multiple media (“growth variants”) to maximize the 
types of biosynthesized natural products.  The percent inhibition from the top hit is also shown.  
Strain 34946 (S. tempisquensis) was explored in chapter 2.  We have begun exploring strain 
44478 for potential novel natural products.    
 
Several other hits from the NPE screen possessed bioactivity against AsbA and SbnE that 
rival the hit pursued in chapter 2 (34946, S. tempisquensis).  Two hits of particular 
interest are 05545 and 44478. Unfortunately, we were unable to regrow strain 05545 
from its freezer stock, a rare but possible problem associated with long-term storage of 
isolated environmental strains. However, strain 44478 grew exceptionally well and 
possessed multiple hits with high bioactivity against both targets during the original 
screen (Table 5-1).    
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I therefore carried out large-scale growth and extraction (10 L) of strain 44478-N5I and 
once again partnered with Dr. Ashootosh Tripathi to fractionate the extract using flash 
chromatography on a C18 cartridge.  I then tested the bioactivity of the resultant fractions 
against both protein targets.  Initial results suggest that multiple fractions have high 
bioactivity against both targets (Figure 5-4).   
 
Figure 5-4. Initial bioactivity of strain 44478-N5I against NIS synthetases SbnE and AsbA. 
Initial fractionation was performed by flash chromatography on a C18 cartridge using varying 
ratios of water (W) to acetonitrile (A). Fractions were tested using the malachite green assay 
outlined in chapter 2.   
 
Future work includes following the strategy outlined in chapter 2 to further fractionate 
this strain and isolate the natural product responsible for the observed bioactivity.  
Following structural elucidation of the compound, dose response assays with any purified 
natural products against both AsbA and SbnE will provide a better idea of potency.  
Testing the purified compounds against siderophore-producing microbial strains like B. 
anthracis, S. aureus, E. coli, S. flexneri, or S. typimurium in both iron-depleted and iron-
rich medium could also provide clues into the specificity of any natural products.  Ideally 
work with this strain will result in the discovery of another novel chemical scaffold with 
potent activity against NRPS-independent siderophore synthetases.  An ideal antibiotic 
would selectivity bind these enzymes over other molecular targets present in the 
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microbial cell.  This would limit selective pressure to iron-depleted conditions, slowing 
microbial acquisition of resistance to the antibiotic (35).           
5.3 Future directions and ongoing work to access the natural products of 
uncultured microorganisms 
Chapters 3 and 4 set the stage for multiple new routes to access the chemotherapeutic 
natural product ET-743.  Although the drug is currently made semi-synthetically (94), the 
process is lengthy and costly.  Synthetic methods also limit our ability to manipulate the 
drug and access more potent and selective analogues through cultivation or heterologous 
expression of key genes or the entire gene cluster.  Future directions and ongoing work 
consists of pursuing multiple different routes to access the chemotherapeutic drug.    
 
Figure 5-5. An outline of current routes being taken to access the chemotherapeutic natural 
product ET-743  
A.) Reconstitute the compound’s core using purified NRPS enzymes in vitro (described in 
chapter 4).  B.) Utilize information gleaned from the genome of Ca. E. frumentensis to cultivate 
the microorganism in a laboratory setting (described here).  C.) Directly produce the natural 
product and new analogous in a cultured host organism through genetic engineering (described 
here).   
 
5.3.1 In vitro reconstitution of the ET-73 biosynthetic core (Figure 5-5A) 
Chapter 4 described initial efforts toward biochemical analysis of NRPS enzymes 
involved in ET-743 biosynthesis and set the stage for future work toward in vitro 
reconstitution of the natural product’s core.   
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Toward this goal, I have been continuing work to increase the solubility of EtuA2 and 
EtuA3 to improve the protein purification yield.  Since the chemical chaperone TMAO 
showed a substantial increase in solubility, it is possible that enzymatic chaperones could 
also improve purification.  I am currently coexpressing enzymatic chaperones and the 
NRPS enzymes to test for solubility improvements.  Acquisition of the remaining NRPS 
modules will provide the essential components to complete in vitro reconstitution of the 
ET-743 biosynthetic core.  We can also test the substrate flexibility of these enzymes as 
we did with EtuA1 and create new analogues through in vitro reactions or 
chemoenzyamtic synthesis.     
 
There are also still some questions regarding the biochemical role of EtuA1, the 
transketolases EtuP1-3, and the ACP EtuF9.  Future work to further analyze the 
enzymatic role of EtuA1 should include biochemical analysis of the enzyme with the rest 
of the NRPS assembly line along with EtuP1-3 and EtuF9.  I have therefore successfully 
cloned codon-optimized versions of the transketolase pyruvate dehydrogenase enzymes 
EtuP1-3 into protein expression vectors.  This will help determine what role—if any—the 
enzymes play in acquiring and/or loading glycolic acid for NRPS use.  It will be 
interesting to see if the enzymes further improve the ability of EtuA1 to activate glycolic 
acid through the malachite green assay.  Alternatively, in vitro enzymatic assays can be 
tested through mass spectrometry to examine whether or not activated glycolic acid is 
being successfully loaded onto EtuA1 in the presence or absence of these other enzymes.  
 
5.3.2 Using metagenomic information to cultivate the producer of ET-743 (Figure 5-
5B) 
The genome of Ca. E. frumentensis presented in chapter 3 provided a detailed look at the 
microbe’s primary metabolism.  This analysis has strengthened our understanding of 
possible nutritional and environmental requirements for cultivation of the microorganism 
in the laboratory.  An ongoing collaboration with the laboratory of Prof. Xiaoxia (Nina) 
Lin from the Chemical Engineering program at the University of Michigan could enable 
host-free cultivation of the microorganism in a laboratory setting (Figure 5-5B). 
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Figure 5-6. Culturing E. turbinata-derived bacteria in a microfluidic device         
A.) 6 droplets at 0 hours. B.) 6 droplets at 26 hours.  Data: (Steven Wang, Scott Mansfield, Dr. 
Jihynang Park, and Prof. Lin) 
 
The collaboration with students Seven Wang and Scott Mansfield from the Lin laboratory 
utilizes a microfluidics device to attempt to cultivate the elusive microorganism.  Bacteria 
isolated from fresh mangrove tunicates are subjected to a variety of different growth 
conditions on the microfluidic device (Figure 5-6) based on our analysis of the complete 
endosymbiont genome.  For example, we now know that the microorganism is incapable 
of producing the majority of amino acids and many key cofactors.  We also know that it 
likely uses an alternative carbon source.  Supplementing growth media and tunicate 
extracts with ingredients like this could finally provide the conditions needed for host-
free cultivation of the evasive microbe (Figure 5-5B).  
 
5.3.3 Biosynthesis of ET-743 or new analogues through a heterologous host like 
Streptomyces lavendulae (Figure 5-5C) 
 
An alternative route to expression and purification of individual enzymes is transferring 
key genes or the complete biosynthetic gene cluster directly into the genome of a 
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heterologous host (Figure 5-5C).  Streptomyces lavendulae represents a particularly 
attractive host since it already biosynthesizes the tetrahydroisoquinoline natural product 
saframycin A.  As we demonstrated in chapter 3, both the saframycin A and ET-743 gene 
clusters have genes predicted to play similar roles during the biosynthesis of the 
corresponding natural products.  Some of the native genes in S. lavendulae may therefore 
be capable of tailoring the ET-743 tetrahydroisoquinoline core in place of the core of 
saframycin A.  This could produce exciting new analogues on a larger scale.    
 
The biggest obstacle with this route is that ET-743 biosynthetic genes—like the majority 
of the Ca. E. frumentensis genome—have an extremely low %G+C content.  As shown in 
chapter 4, this contributes significantly to codon incompatibility observed with many 
heterologous hosts, S. lavendulae included.  Codon optimized genes are the easiest way 
to combat this problem.  To solve this dilemma, we have codon optimized the three 
NRPS genes responsible for the biosynthesis of the ET-743 core for expression in 
varying Streptomyces species.  We have also begun collaborating with the laboratory of 
Dr. Eung-Soo Kim at Inha University in Korea.  The laboratory is using their expertise in 
actinomyces genetics to attempt to biosynthesize ET-743 and analogues in different 
species, including the saframycin A producer, S. lavendulae.   
 
5.4 Conclusions  
The chapters of this dissertation have described significant efforts to explore and harness 
the natural products of both cultured and uncultured bacteria. The methodologies outlined 
here (targeted high throughput screening, metagenomic techniques to acquire and analyze 
complete genomes, in vitro reconstitution) can be applied to other natural product studies.  
Utilizing these and other available techniques will provide a better understanding of the 
world’s microbial diversity and how we can harness that diversity to access novel 
medicines for our fight against drug resistant infections.      
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